

PRAKASH S. MASAND, M.D.
26 E. 63rd Street, Suite 11 F, New York, NY 10065
(212) 633-0003 · pmasand2001@yahoo.com

Consulting Professor of Psychiatry & Behavioral Sciences,
Department of Psychiatry, Duke University Medical Center, Durham, NC

CURRICULUM VITAE

PROFESSIONAL OVERVIEW

Prakash Masand, MD, is a Consulting Professor of Psychiatry and Behavioral Sciences at Duke University Medical Center in Durham, North Carolina. Dr Masand was also most recently Director, Therapeutic Area Development, Neurosciences Medicine, Duke Clinical Research Institute. He is also the former President and CEO of psychCME, Inc., a continuing medical education company he founded in 2001, which was acquired in 2006 by Ingenix, a division of United Health Care. He serves as a consultant to a variety of health care organizations and publications and is a member of the advisory board for many pharmaceutical companies. He is the Past President of the Central New York District Branch of the APA and serves on various national committees. He is a Distinguished Fellow of the APA and the Academy of Psychosomatic Medicine.

Dr. Masand has published more than 300 articles, abstracts, reviews and book chapters in many of the nation's leading peer-reviewed journals. He serves on the editorial board and as a peer reviewer for several journals. Dr. Masand has given more than 2000 invited presentations around the United States and abroad. He was voted Teacher of the Year twice at SUNY Upstate Medical University Department of Psychiatry. He is also the recipient of the 2008 Outstanding Academician award from the Indo-American Psychiatric Association.

Dr. Masand's clinical research interests include psychopharmacology, novel antipsychotics, psychiatric disorders in the medically ill, treatment resistant depression, irritable bowel syndrome and its relationship to psychiatric illness and use of psychostimulants in the medically ill.

Dr. Masand graduated from the Topiwala National Medical College, Bombay, India. He completed his residency training in psychiatry at the SUNY Upstate Medical University at Syracuse and a Fellowship in Consultation-Liaison Psychiatry at the Massachusetts General Hospital, Harvard Medical School.

TABLE OF CONTENTS

PROFESSIONAL OVERVIEW	1
SPECIALTY CERTIFICATIONS	3
MEDICAL LICENSE NUMBERS	3
AREAS OF RESEARCH INTEREST	3
EDUCATION	3
PROFESSIONAL APPOINTMENTS	3
ACADEMIC APPOINTMENTS	3
CONSULTING APPOINTMENTS	4
EDITORIAL APPOINTMENTS	4
JOURNAL REVIEWER	4
PROFESSIONAL TRAINING AND ACADEMIC ADMINISTRATIVE APPOINTMENTS	5
PUBLICATIONS	6
In Press	6
Published Articles	6
Submitted for Publication	21
Book Chapters	21
Newsletters	22
Selected Abstracts	233
TELEVISION APPEARANCES	35
PROFESSIONAL AWARDS AND SPECIAL RECOGNITION	40
ELECTED POSITIONS AND COMMITTEE INVOLVEMENT	41
COURSES TAUGHT	41
SPEAKING ENGAGEMENTS	43
RESEARCH GRANTS AND CONTRACTS	48
PROFESSIONAL MEMBERSHIPS	49
ACADEMIC/ADMINISTRATIVE ACTIVITIES AT THE UNIVERSITY LEVEL	50

SPECIALTY CERTIFICATIONS

American Board of Psychiatry and Neurology, November 1990

MEDICAL LICENSE NUMBERS

New York: 175052 (active)

North Carolina: 200101368 (inactive)

Massachusetts: 59421 (inactive)

AREAS OF RESEARCH INTEREST

- Comorbidity of Psychiatric Illness in Irritable Bowel Syndrome
- Compliance Issues in Psychiatry
- Pharmacotherapy of Fibromyalgia
- Pharmacotherapy of Irritable Bowel Syndrome
- Use of Psychostimulants in the Medically Ill
- Weight Gain in Patients on Atypical Antipsychotics

EDUCATION

Topiwala National Medical College, University of Bombay, MBBS, 1981

Jai Hind College, University of Bombay, Pre-Med, 1977

St. Xavier's High School, Bombay India; H.S. Diploma, 1975

PROFESSIONAL APPOINTMENTS

Sr. VP, Medical Affairs	Ingenix, a division of United HealthGroup	2006-2007
President, CEO and Founder	psychCME, Inc.	2004-2006

ACADEMIC APPOINTMENTS

Consulting Professor	Department of Psychiatry and Behavioral Sciences Duke University Medical Center, Durham, NC	2004 - present
Clinical Professor	Department of Psychiatry New York University Medical Center New York, NY	2007 – 2008
Clinical Professor	Department of Psychiatry and Behavioral Sciences Duke University Medical Center, Durham, NC	2001 - 2004
Tenured Professor	Department of Psychiatry, State University of New York (S.U.N.Y.) Upstate Medical University, Syracuse, NY	1997 - 2001
Tenured Associate Professor	Department of Psychiatry State University of New York (S.U.N.Y.)	1993 - 1997

Upstate Medical University, Syracuse, NY

Assistant Professor Department of Psychiatry 1989 - 1993
State University of New York (S.U.N.Y.)
Upstate Medical University, Syracuse, NY

CONSULTING APPOINTMENTS

- Psychopharmacology Consultant to Office of Mental Health/Hutchings Psychiatric Center, Syracuse, NY, 1989 - 1999
- Department of Social Services, Onondaga County, Syracuse, NY, 1991-2001
- Psychiatric Consultant, Hepatic-Biliary-Pancreas Center, SUNY Health Science Center, Syracuse, NY, 1993 – 1999
- Psychopharmacology Consultant, Onondaga Pastoral Counseling Center, Syracuse, NY, 1990-1995
- Psychopharmacology Consultant to Syracuse V.A. Medical Center - 1990

EDITORIAL APPOINTMENTS

- Editorial Board, *Open Pharmacology Journal*, 2006 – present
- Editorial Board, *Archives of Indian Psychiatry*, 1999 – present
- Editorial Board, *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 2005 – present
- Editorial Board, *Social Science and Medicine*, 2005 – present
- Editorial Board, *Current Clinical Pharmacology*, 2005 – present
- Editor, *psychCME Reports*, 2002 – 2004
- Editorial Board, *Mental Fitness*, 2003 – present
- Editorial Board, *Annals of Clinical Psychiatry*, 2003 – present
- Editorial Board, *Primary Care Companion to Journal of Clinical Psychiatry*, 1999 – present
- Editor, *Journal of Clinical Psychiatry JCP Visuals*, 1999 – present
- Section Editor, *Current Psychiatry Reports*, 1999 – 2008
- Editorial Board, *Journal of Psychotic Disorders*, 1996 – present
- Editor, *Eye on Psychiatry*, 1996 – 1998

JOURNAL REVIEWER

- *American Journal of Gastroenterology*
- *Biological Psychiatry*
- *Current Psychiatry Reports*
- *International Journal of Clinical Psychiatry*
- *Journal of Clinical Psychiatry*
- *Journal of Geriatric Psychiatry and Neurology*
- *Journal of Gerontology: Medical Sciences*
- *Journal of Intensive Care Medicine*
- *Journal of Neuropsychiatry and Clinical Neurosciences*
- *Journal of Psychosomatic Research*
- *Mayo Clinic Proceedings*
- *Primary Care Companion to the Journal of Clinical Psychiatry*
- *Psychosomatic Medicine*

- *Psychosomatics*
- *Schizophrenia Research*
- VA Merit Review Grant

PROFESSIONAL TRAINING AND ACADEMIC ADMINISTRATIVE APPOINTMENTS

Director Duke University Medical Center	Psychopharmacology Consultation Program,	2001-2004
Director Duke University Medical Center	Program for Continuing Medical Education,	2001-2004
Director Training and Research Program	Regional Psychopharmacology Consultation,	1995-2001
Director (S.U.N.Y.) Upstate Medical University	Psychiatric Consultation Service	1992-1999
Associate Director (S.U.N.Y.) Upstate Medical University	Adult Psychiatry Outpatient Clinic	1991-1992
Associate Director (S.U.N.Y.) Upstate Medical University	Psychiatric Consultation Service	1991-1992
Associate Director (S.U.N.Y.) Upstate Medical University	Psychiatry Inpatient Unit	1989-1991
Fellowship Massachusetts General Hospital Harvard Medical School	Consultation-Liaison Psychiatry	July 1988 - June 1989
Residency in Psychiatry (S.U.N.Y.) Upstate Medical University, Syracuse, NY	Psychiatry: State University of New York	July 1985 - June 1988
Residency in Psychiatry Bombay	Topiwala National Medical College,	October 1982 - August 1984
Clerkship in Psychiatry	Beth Israel Hospital, Boston	October 1984 – November 1984
Clerkship in Psychiatry	Massachusetts General Hospital, Boston	September 1984 – October 1984
Rotating Internship	Topiwala National Medical College	October 1981 - October 1982

PUBLICATIONS

Published Articles

1. Pae CU, Koh JS, Lee SJ, Han C, Patkar AA, Masand PS. Association of sedative-hypnotic medications with suicidality. *Expert Rev Neurother*. 2011 Mar;11(3):345-349.
2. Seo HJ, Chiesa A, Lee SJ, Patkar AA, Han C, Masand PS, Serretti A, Pae CU. Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications. *Clin Neuropharmacol*. 2011 Jan-Feb;34(1):39-47.
3. Masand P, O'Gorman C, Mandel FS. Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data. *Schizophr Res*. 2011 Mar;126(1-3):174-183.
4. Pae C, Sohi M.S., Seo HJ, Serretti A, Patkar AA, Steffens DC, Masand PS. Quetiapine XR: Current status for the treatment of major depressive disorder. *Prog Neuropsychopharmacol Biol Psychiatry*. 2010 1;34(7):1165-73.
5. Seo HJ, Sohi MS, Patkar AA, Masand PS, Pae CU. Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms. *Postgrad Med*. 2010;122(1):125-38.
6. Pae CU, Misra A, Ham BJ, Han C, Patkar AA, Masand PS. Paroxetine mesylate: comparable to paroxetine hydrochloride? *Expert Opin Pharmacother*. 2010;11(2):185-93.
7. Pae CU, Masand PS, Marks DM, Krulewicz S, Peindl K, Mannelli P, Patkar AA. History of depressive and/or anxiety disorders as a predictor of treatment response: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia. *Prog Neuropsychopharmacol Biol Psychiatry*. 2009;33(6):996-1002.
8. Marks DM, Shah MJ, Patkar AA, Masand PS, Park GY, Pae CU. Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise. *Curr Neuropharmacol*. 2009;7(4):331-6.
9. Han C, Pae CU, Patkar A, Masand PS, Kim KW, Joe SH, Jung IK: Psychometric Properties of the Patient Health Questionnaire-15 (PHQ-15) for Measuring the Somatic Symptoms of Psychiatric Outpatients. *Psychosomatics*. 2009;50(6):580-5.
10. Pae CU, Patkar AA, Marks D, Han C, Masand P, Ham BJ. Milnacipran: beyond a role of antidepressant. *Clin Neuropharmacol*. 2009;32(6):355-63.
11. Marks DM, Patkar AA, Masand PS, Pae CU. Does pregabalin have neuropsychotropic effects?: a short perspective. *Psychiatry Investig*. 2009;6(2):55-8.

12. Pae CU, Tharwani H, Marks DM, Masand PS, Patkar AA.. Atypical depression: a comprehensive review. *CNS Drugs*. 2009 1;23(12):1023-37.
13. Masand PS, Roca M, Turner MS, Kane JM. Partial adherence to antipsychotic medication impacts the course of illness in patients with Schizophrenia: a review. *Prim Care Companion J Clin Psychiatry*. 2009;11(4):147-154.
14. Pae CU, Marks DM, Patkar AA, Masand PS, Luyten P, Serretti A. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. *Expert Opin Pharmacother*. 2009;10(10):1561-1570.
15. Pae CU, Marks DM, Masand PS, Peindl K, Hooper-Wood C, Han C, Mannelli P, Ciccone P, Patkar AA. Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial. *Clin Neuropharmacol*. 2009;32(2):85-88.
16. Pae CU, Mandelli L, Han C, Ham BJ, Masand PS, Patkar AA, Steffens DC, De Ronchi D, Serretti A. Thyroid hormones affect recovery from depression during antidepressant treatment. *Psych Clin Neurosciences*. 2009;63(3):305-313.
17. Pae CU, Masand PS, Marks DM, Krulewicz S, Han C, Peindl K, Mannelli P, Patkar AA. History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. *World J Biol Psychiatry*. 2009;April 20:1-7.
18. Masand PS, Pae CU, Krulewicz S, Peindl K, Mannelli P, Varia IM, Patkar AA. A double-blind, randomized, placebo-controlled, trial of paroxetine controlled-release in irritable bowel syndrome. *Psychosomatics*. 2009;50(1):78-86.
19. Pae CU, Patkar AA, Masand PS. Augmentation of dopaminergic agents for major depressive disorder. *J Clin Psychiatry*. 2009;70(3):432-433; author reply 433-434.
20. Han C, Masand PS, Krulewicz S, Peindl K, Mannelli P, Varia IM, Pae CU, Patkar AA. Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. *J Clin Pharm Ther*. 2009;34(1):79-88.
21. Pae CU, Park MH, Marks DM, Han C, Patkar AA, Masand PS. Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. *Curr Opin Investig Drugs*. 2009;10(1):75-90.
22. Han C, Kwak KP, Marks DM, Pae CU, Wu LT, Bhatia KS, Masand PS, Patkar AA. The impact of CONSORT statement on reporting of randomized clinical trials in psychiatry. *Contemp Clin Trials*. 2009;30(2):116-122.

23. Pae CU, Marks DM, Han C, Masand PS, Patkar AA. Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study. *Int Clin Psychopharmacol*. 2009;24(1):29-33.
24. Pae CU, Marks DC, Han C, Patkar AA, Masand PS. Duloxetine: an emerging evidence for fibromyalgia. *Biomed Pharmacother*. 2009;63(1):69-71.
25. Pae CU, Mandelli L, Kim TS, Han C, Masand PC, Marks DM, Patkar AA, Steffens DC, De Ronchi D, Serretti A. Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects. *Biomed Pharmacother*. 2009;63(3):228-235.
26. Pae CU, Serretti A, Patkar AA, Masand PS. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. *CNS Drugs*. 2008;22(5):367-388.
27. Narasimhan M, Pae CU, Srinivasan S, Masand P. Profile of Paliperidone Extended Release: Review of Efficacy and Safety Data. *Expert Review of Clinical Pharmacology*. 2008 1(6):729-736.
28. Pae CU, Masand P. Duloxetine: a new psychopharmacologic treatment option for fibromyalgia? *Curr Psychiatry Rep*. 2008;10(3):237-239.
29. Masand PS, Eudicone J, Pikalov A, McQuade RD, Marcus RN, Vester-Blokland E, Carlson BX. Criteria for defining symptomatic and sustained remission in bipolar 1 disorder: a post-hoc analysis of a 26-week aripiprazole study (study CN138-010). *Psychopharmacol Bull*. 2008;41(2):12-23.
30. Marks DM, Park MH, Ham BJ, Han C, Patkar AA, Masand PS, Pae CU. Paroxetine: safety and tolerability issues. *Expert Opin Drug Saf*. 2008;7(6):783-794.
31. Pae CU, Mandelli L, Han C, Ham BJ, Masand PS, Patkar AA, Steffens DC, DeRonchi D, Serretti A. Do estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women. *Neuro Endocrinol Lett*. 2008 29(4):500-506.
32. Marks DM, Han C, Krulewicz S, Pae CU, Peindl K, Patkar AA, Masand PS. History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled study. *Prim Care Companion J Clin Psychiatry*. 2008;10(5):368-375.
33. Pae CU, Masand PS, Peindl K, Mannelli P, Han C, Marks DM, Patkar AA. An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive with atypical features. *Prim Care Companion J Clin Psychiatry*. 2008;10(3):205-210.

34. Han C, Pae CU, Lee BH, Ko YH, Masand PS, Patkar AA, Joe SH, Jung IK. Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: a 12-week prospective, open-label, randomized, parallel-group trial. *Clin Drug Investig.* 2008;28(4):251-261.
35. Han CS, Pae CU, Lee BH, Ko YH, Masand PS, Patkar AA, Jung IK. Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: a randomized, open-label, 12-week, parallel-group trial. *Prog Neuropsychopharmacol Biol Psychiatry.* 2008;32(2):437-444.
36. Pae CU, Marks DM, Han C, Patkar AA, Masand P. Delirium: where do we stand? *Curr Psychiatry Rep.* 2008;10(3):240-248.
37. Pae CU, Luyten P, Marks DM, Han C, Park SH, Patkar AA, Masand PS, Van Houdenhove B. The relationship between fibromyalgia and major depressive disorder: a comprehensive review. *Cur Med Res Opin.* 2008;24(8):2358-2371.
38. Pae CU, Marks DM, Han C, Patkar AA, Masand P. Delirium: underrecognized and undertreated. *Cur Treat Options Neurol.* 2008;10(5):386-395.
39. Narasimhan M, Masand P. Depressive subtype a predictor of cardiovascular morbidity. *Cur Psychiatry Pre.* 2008;10(3):191-194.
40. Narasimhan M, Travis BO, Masand PS. Review of olanzapine in the management of bipolar disorders. *Neuropsychiatric Disease and Treatment.* 2007;3(5):579-587.
41. Mannelli P, Peindl K, Masand PS, Patkar AA. Long-acting injectable naltrexone for the treatment of alcohol dependence. *Expert Rev Neurother.* 2007;7(10):1265-77.
42. Pae CU, Lim HK, Han C, Patkar AA, Steffens DC, Masand PS, Lee C. Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion. *Expert Rev Neurother.* 2007;7(10):1251-1263.
43. Pae CU, Masand PS, Ajwani N, Lee C, Patkar AA. Irritable bowel syndrome in psychiatric perspectives: a comprehensive review. *Int J Clin Pract.* 2007;61(10):1708-1718.
44. Iqbal N, Lambert T, Masand P. Akathisia: problem of history or concern of today. *CNS Spectr.* 2007;9 (Suppl 14):1-13.
45. Narasimhan M, Pae CU, Masand N, Masand PS. Partial compliance with antipsychotics and its impact on patient outcomes. *Intl J Psychiatry Clin Pract* 2007;11(2):102-111.
46. Gupta S, Nihalani N, Masand P. Duloxetine: review of its pharmacology, and therapeutic use in depression and other psychiatric disorders. *Ann Clin Psychiatry.* 2007;19(2):125-32.
47. Radhakrishnan M, Masand P. Prevalence of PTSD following surgical amputation. *Curr Psychiatry Rep.* 2007;9(3):215-6.

48. Tharwani HM, Yerramsetty P, Manelli P, Patkar A, Masand PS. Recent advances in post-stroke depression. *Curr Psychiatry Rep.* 2007;9(3):225-31.
49. Patkar AA, Masand PS, Krulewicz S, Mannelli P, Peindle K, Beebe KL, Jiang W. A randomized, controlled trial of controlled release paroxetine in fibromyalgia. *Am J Med.* 2007;120(5):448-454.
50. Pae CU, Kim JJ, Lee SJ, Lee CU, Lee C, Paik IH, Masand PS. Rapid versus conventional initiation of quetiapine in the treatment of schizophrenia: a randomized, parallel-group trial. *J Clin Psychiatry.* 2007;68(3):399-405.
51. Masand PS. Differential pharmacology of atypical antipsychotics: clinical implications. *Am J Health Syst Pharm.* 2007;64(Suppl 1):S3-8.
52. Pae CU, Patkar AA, Jun TY, Lee C, Masand PS, Paik IH. Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. *Depress Anxiety.* 2007;24(7):522-526.
53. Peindl KS, Masand P, Mannelli P, Narasimhan M, Patkar A. Polypharmacy in pregnant women with major psychiatric illness: a pilot study. *J Psychiatr Pract.* 2007;13(6):385-392.
54. Masand, PS, Tharwani HM, and Patkar AA. Polypharmacy in schizophrenia, *Intl J Psychiatry Clin Pract* 2006;10(4):258-263.
55. Patkar AA, Pae CU, Masand PS. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. *CNS Spectr.* 2006;11(5):363-375.
56. Pae CU, Nassir Ghaemi S, Patkar A, Chae JH, Bahk WM, Jun TY, Masand P. Adjunctive risperidone, olanzapine and quetiapine for the treatment of hospitalized patients with bipolar I disorder: A retrospective study. *Prog Neuropsychopharmacol Biol Psychiatry.* 2006;30:1322-1325.
57. Pae CU, Kim TS, Lee KU, Kim JJ, Patkar AA, Masand PS, Ghaemi SN, Lee CU, Lee SJ, Lee C, Paik IH. Clinical variables associated with early administration of antipsychotics in bipolar mania. *Prog Neuropsychopharmacol Biol Psychiatry.* 2006;30(1) 151-154.
58. Patkar AA, Peindl K, Mago R, Mannelli P, Masand PS. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. *Prim Care Companion J Clin Psychiatry.* 2006;8(2):82-87.
59. Narasimhan M, Masand P. Metabolic Syndrome in patients with schizophrenia: CATIE results. Clinical Trial Reports. *Curr Psych Reports* 2006.
60. Masand P, Narasimhan M. Major depressive disorder and mental illness: STAR*D Outcomes. Commentary. *Curr Psych Reports* 2006.

61. Masand PS, Narasimhan M, Patkar AA. Paroxetine for somatic pain associated with physical illness: a review. *Prim Care Companion J Clin Psychiatry*. 2006;8(3):122-130.
62. Masand PS, and Narisimhan M. Improving adherence to antipsychotic pharmacotherapy. *Curr Clin Pharmacol*. 2006;1(1):47-56.
63. Patkar A, Masand P, Pae C, Peindl K, Hooper-Wood C, Mannelli P, Ciccone P. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. *J Clin Psychopharmacol*. 2006;26:653-656.
64. Masand P, Culpepper L, Henderson D, Lee S, Littrell K, Newcomer J, Rasgon N. Prevalence of irritable bowel syndrome in obsessive compulsive disorder. *CNS Spectr*. 2006;11(1):21-25.
65. Ramaswamy K, Masand PS, Nasrallah HA. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. *Ann Clin Psychiatry*. 2006;18:183-194.
66. Narasimhan M, Gupta S, Masand P. Management of antipsychotic induced weight gain. *Psych Times* 2005.
67. Masand PS, Nemeroff CB, Lieberman JA, Weiden PJ, Harvey PD, Newcomer JW, Schatzberg AF, Kilts CD, Daniel DG. From clinical research to clinical practice: a 4-year review of ziprasidone. *CNS Spectr*. 2005;11:1-20.
68. Masand PS, Culpepper L, Henderson D, Lee S, Littrell K, Newcomer JW, Rasgon N. Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization. *CNS Spectr*. 2005;10(10):Suppl 14 1-15.
69. Masand PS, Devitt P and Patkar A. Comparison of risperidone and conventional neuroleptics in patients admitted to a forensic hospital. *Arch of Indian Psychiatry*. 2005; 7:20-22.
70. Masand PS. A review of pharmacologic strategies for switching to atypical antipsychotics. *Prim Care Companion J Clin Psychiatry*. 2005;7(3):121-129.
71. Gupta S, Narisimhan M, Masand PS. Management of antipsychotic-induced weight gain. *Psychiatr Times*. 2005; 22:75-79.
72. Masand PS, Gupta S, Schwartz TL, Virk S, Hameed A, Kaplan DS. Open-label treatment with citalopram in patients with irritable bowel syndrome: a pilot study. *Prim Care Companion J Clin Psychiatry*. 2005;7(4):162-166.
73. Masand PS, Mago R. Duloxetine for pain symptoms in patients with major depressive disorder. *Curr Psychiatry Rep*. 2005;7(3):203-205.

74. Gupta S, Masand P, Madhusoodanan S. Side effects of atypical antipsychotics in the geriatric population. *Curr Psychosis and Therapeutics Rep.* 2005;3:26-31.
75. Masand PS, Mago R. Second-generation antipsychotics and the metabolic syndrome. *Curr Psychiatry Rep.* 2005;7(3):153-154.
76. Masand P, Mago R. Review: in people with bipolar disorder, short term antidepressants improve clinical response, although tricyclics risk inducing mania. *Evid Based Ment Health.* 2005;8:35.
77. Masand PS. Clinical effectiveness of atypical antipsychotics in elderly patients with psychosis. *Eur Neuropsychopharmacol.* 2004;14:461-469.
78. Masand PS, Fazal FS, Patkar AA. Safety considerations in pharmacotherapy of bipolar disorder. *CNS Spectr.* 2004;9(11 Suppl 12):16-26.
79. Masand PS. Depression – Treatment and unmet medical needs. *Clin Psych News.* 2004;6-9.
80. Fava M, Harvey P, Masand P, Papakostas G. Atypical antipsychotics in treatment-resistant depression. *Clin Psych News.* 2004; 4-11.
81. Patkar AA, Bilal L, Masand PS. Pharmacotherapy of depression in pregnancy. *Ann Clin Psych.* 2004;16(2):87-100.
82. Masand, PS. Atypical antipsychotics in the treatment of affective symptoms: a review. *Ann Clin Psych.* 2004;16:3-13.
83. Gupta S, Masand P. Aripiprazole: Review of its pharmacology and therapeutic use in psychiatric disorders. *Ann Clin Psych.* 2004;16:155-166.
84. Patkar AA, Mago R, Masand PS. Psychotic symptoms in patients with medical disorders. *Curr Psychiatry Rep.* 2004;6(3):216-224.
85. Gupta S, Masand PS, Virk S, Schwartz T, Hameed A, Frank BL, Lockwood K. Weight decline in patients switching from olanzapine to quetiapine. *Schizophr Res.* 2004;70(1):57-62.
86. Masand PS, Gupta S. Depot antipsychotics in the older patient: guideline for effective use. *Drugs and Aging.* 2003;14:175-182.
87. Masand P, Gupta S. Long-Acting injectable antipsychotics in the elderly: guidelines for effective use. *Drugs Aging.* 2003;20(15):1099-1110.
88. Masand PS, Gupta S. Quality of life issues associated with antipsychotic-induced weight gain. *Expert Rev Pharmacoeconomics Outcomes Res.* 2003;3:651-659.

89. Masand PS, Gupta S. The safety of SSRIs in generalized anxiety disorder: any reason to be anxious? *Expert Opin Drug Saf.* 2003;2(5):485-493.
90. Masand PS. Tolerability and adherence issues in antidepressant therapy. *Clin Ther.* 2003;25(8):2289-2304.
91. Sharma S, Pinto C, Masand PS, Virk S, Kaplan D, Nihalani N, Gupta S. Relationship of irritable bowel syndrome (IBS) and major depression in Mumbai, India. *Int J of Psychiatry in Clin Practice.* 2003;7:127-130.
92. Patkar AA, Bilal L, Masand PS. Management of fibromyalgia. *Curr Psychiatry Rep.* 2003;5(3):218-224.
93. Garakani A, Win T, Virk S, Gupta S, Kaplan D, Masand PS. Comorbidity of irritable bowel syndrome in psychiatric patients: a review. *Am J Ther.* 2003;10(1):61-67.
94. Masand PS. Gender differences in antidepressant response. *Curr Psychiatry Rep.* 2003;5(3):209-210.
95. Masand PS. Antipsychotic treatment in older patients. *ElderCare.* 2002;2:5-8.
96. Schwartz TL, Saba M, Hardoby W, Virk S, Masand, PS. Use of atypical antipsychotics in a veterans affairs hospital. *Prog Neuropsychopharmacol Biol Psychiatry.* 2002;26(6):1207-1210.
97. Masand PS, Gupta S, Schwartz TL, Kaplan DS, Virk S, Hameed A, Lockwood K. Does a preexisting anxiety disorder predict response to paroxetine in irritable bowel syndrome (IBS)? *Psychosomatics.* 2002;43(6):451-455.
98. Masand PS, Schwartz TL, Wang X, Kuhles DJ, Gupta S, Agharkar B, Manjooran J, Hameed MA, Hardoby W, Virk S, Frank B. Prescribing conventional antipsychotics in the era of novel antipsychotics: informed consent issues. *Am J Ther.* 2002;9(6):484-487.
99. Masand PS, Gupta S. Long-term side effects of newer generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion and mirtazapine. *Ann Clin Psychiatry.* 2002;14(3):175-182.
100. Masand PS, Wang X, Gupta S, Schwartz TL, Virk S, Hameed A. Comparison of risperidone and olanzapine in bipolar and schizoaffective disorders. *Prim Care Companion J Clin Psychiatry.* 2002;4(2):70-73.
101. Schwartz TL, Masand PS. Role of atypical antipsychotics in the treatment of delirium. *Psychosomatics.* 2002; 43(3):171-174.
102. Masand PS, Gupta S, Schwartz TL, Virk S, Lockwood K, Hameed A, King M, Kaplan DS. Paroxetine in patients with irritable bowel syndrome (IBS): a pilot open-label study. *Prim Care Companion J Clin Psychiatry.* 2002;4(1):12-16.

103. Ashton A, Masand PS, Gupta S, Frank BL: Bupropion and sexual dysfunction. *Am J Psychiatry*. 2002;159:677-678.
104. Kunwar A, Virk S, Masand PS. Urinary incontinence with mirtazapine. *J Clin Psychiatry*. 2002; 63(5):454.
105. Masand PS. Dr. Masand Replies. *Prim Care Companion J Clin Psychiatry*. 2002;4(3):114.
106. Masand PS. Clinical trials report. *Curr Psychiatry Rep*. 2001;3:217.
107. Masand PS. Olanzapine versus other antipsychotics in the treatment of schizophrenia. *J Clin Psychiatry*. 2001;62(10):828-829.
108. Kubal TV, Pinto C, Masand PS, Virk S, Sharma S, Kaplan D, Yu-Siao B, Gupta S. Relationship of irritable bowel syndrome (IBS) and panic disorder in Mumbai, India. *Prim Psychiatry*. 2001;8:33-35.
109. Gupta S, Masand PS, Kothari AJ. Cardiovascular side effects of novel antipsychotics. *CNS Spectr*. 2001;6(11):912-918.
110. Masand PS, Arora M, Schwartz TL, Sharma A, Wang X, Bhatia S, Manjooran J, Hardoby W, Virk S, Kuhles D, Agharkar B, Gupta S. Prescribing conventional antipsychotics at two veterans administration hospitals: are there geographical differences? *CNS Spectr*. 2001;6(11):894-896.
111. Masand PS. Treating psychosis in the new millennium. *CNS Spectr*. 2001;6(11):891.
112. Schwartz TL, Kuhles DJ, Wade M, Masand PS. Newly admitted psychiatric patient prescriptions and pharmaceutical sales visits. *Ann Clin Psych*. 2001;3(3):159-162.
113. Masand PS. Role of novel antipsychotics in delirium. *J Psychotic Disorders*. 2001;5:8-9.
114. Masand PS, Ashton A, Gupta S, Bradford F. Sustained-release bupropion for SSRI-induced sexual dysfunction: a randomized double-blind placebo-controlled, parallel group study. *Am J Psychiatry*. 2001;158(5):805-807.
115. Masand PS. Clinical trials report. *Curr Psychiatry Rep*. 2000;2:231-233.
116. Masand PS. The use of antipsychotic agents in dementia. *AAPI Journal*. Fall 2000;27-30.
117. Schwartz TL, Masand PS, Alao K. Research priorities in electroconvulsive therapy. *Arch Indian Psychiatr*. 2000;6:176-179.
118. Gupta S, Masand PS. Effect of citalopram on blood desipramine levels. *Prim Care Companion J Clin Psychiatry*. 2000;2(1):28.

119. Gupta S, Masand P, Virk S. Acetylcholinesterase inhibitors: treatment of dementia related behavioral disturbances. *Prim Care Companion J Clin Psychiatry*. 2000; 2:227-228.
120. Schwartz TL, Kuhles DJ, Beeber AR, Gregory RJ, Masand PS. Pharmaceutical industry impact on prescribing practices of psychiatry residents. *TEN*. 2000;2:47-49.
121. Gregory RJ, Masand PS, Yohai N. Depression across the reproductive life cycle: correlations between events. *Prim Care Companion J Clin Psychiatry*. 2000;2(4):127-129.
122. Masand PS, Gupta S. Long-term adverse effects of novel antipsychotics. *J Psychiatr Pract*. 2000;6(6):299-309.
123. Schwartz TL, Boylan D, Masand PS, Kuhles, DJ, Gupta S, Chengappa KNR, Ahmed S, Parepally H. Clinical effectiveness of divalproex sodium in lithium carbonate refractory bipolar spectrum patients. *Pharmacy & Therapeutics*. 2000;25:410-418.
124. Masand PS. Novel antipsychotics in the treatment of behavioral disturbances and psychoses associated with neurodegenerative disorders. *Prim Care Companion J Clin Psychiatry*. 2000;2(3):80-88.
125. Gupta S, Frank B, Keller P, Masand PS. Topiramate in bipolar and schizoaffective disorders: weight loss and efficacy. *Prim Care Companion J Clin Psychiatry*. 2000;2(3):96-100.
126. Isakov I, Klesmer J, Masand PS. Insulin-resistant hyperglycemia induced by clozapine. *Psychosomatics*. 2000;41(4):373-374.
127. Masand PS. Weight gain associated with psychotropic drugs. *Expert Opin on Pharmacother*. 2000;1(3):377-389.
128. Ashton AK, Ahrens K, Gupta S, Masand PS. Antidepressant-induced sexual dysfunction and ginkgo biloba. *Am J Psychiatry*. 2000;157(5):836-837.
129. Masand PS. Side effects of antipsychotics in the elderly. *J Clin Psychiatry*. 2000;61(Suppl 8):43-49.
130. Schwartz TL, Masand PS. Treatment of delirium with quetiapine. *Prim Care Companion J Clin Psychiatry*. 2000;2(1):10-12.
131. Gupta S, Al-Samarrai S, Masand PS, Lentz BJ, Keller PJ, Droney TM. Real-world outcomes of once-daily risperidone dosing. *Prim Care companion J Clin Psychiatry*. 2000;2(2):55-57.
132. Gupta S, Masand PS. Citalopram and hair loss. *Prim Care Companion J Clin Psychiatry*. 2000;2(2):61-62.
133. Gupta S, Frank BL, Masand PS. Gabapentin in the treatment of aggression associated with conduct disorder. *Prim Care Companion J Clin Psychiatry*. 2000;2(2):60-61.

134. Schwartz TL, Massa JL, Gupta S, Al-Samarri S, Devitt P, Masand PS. Divalproex sodium versus valproic acid in hospital treatment of psychotic disorders. *Prim Care Companion J Clin Psychiatry*. 2000;2(2):45-48.
135. Masand PS, Berry SL. Switching antipsychotic therapies. *Ann Pharmacother*. 2000;34(4):200-207.
136. Masand PS. Atypical antipsychotics for elderly patients with neurodegenerative disorders and medical conditions. *Psychiatr Ann*. 2000;30:202-208.
137. Gupta S, Masand PS, Ashton A, Berry S. Phenelzine-induced sexual dysfunction treated with sildenafil. *J Sex and Marital Ther*. 1999;25:131-135.
138. Masand PS, Alao K. Atypical antipsychotics and weight gain. *Arch Indian Psychiatry*. 1999;5:146-147.
139. Gupta S, Masand PS, Black DW. Sertindole: review of its pharmacology and indications in clinical practice. *Arch Indian Psychiatry*. 1999;5:16-24.
140. Gupta S, Mosnik D, Black DW, Berry S, Masand PS. Tardive dyskinesia: review of treatments: past, present, and future. *Ann Clin Psychiatry*. 1999;11(4):257-266.
141. Masand PS. Introduction. Weight gain with psychotropics: size does matter. *J Clin Psychiatry*. 1999;60(Suppl 21):3-4.
142. Gupta S, Droney T, Masand PS, Ashton AK. SSRI-induced sexual dysfunction treated with sildenafil. *Depress Anxiety*. 1999;9:180-182.
143. Masand PS, Gupta S. Selective serotonin-reuptake inhibitors: an update. *Harv Rev Psychiatry*. 1999;7(2):69-84.
144. Masand PS. Weight gain unfairly characterizes some atypical antipsychotics. *J Clin Psychiatry*. 1999;60:336-337.
145. Masand PS, ed. JCP Visuals. Weight gain and antipsychotic medications. *J Clin Psychiatry*. 1999.
146. Masand PS. Relative weight gain among antipsychotics. *J Clin Psychiatry*. 1999;60(10):706-708.
147. Gupta S, Masand PS, Ashton AK, Berry SL. Phenelzine-induced sexual dysfunction treated with sildenafil. *J Sex Marital Ther*. 1999; 25:131-135.
148. Masand PS. Weight gain associated with atypical antipsychotics. *J Psychotic Disorders*. 1998; 2:4-6.

149. Gupta S, Masand PS. Clinical simulations in the management of psychotic disorders, case 7. *Medical Age Publishing*, 1998.
150. Meltzer H, Casey D, Garver D, Lasagna L, Marder S, Masand P, Miller D, Pickar D, Tandon R. Treatment of special populations with the atypical antipsychotics. *J Clin Psychiatry*. 1998;59:46-52.
151. Meltzer H, Casey D, Garver D, Lasagna L, Marder S, Masand P, Miller D, Pickar D, Tandon R. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. *J Clin Psychiatry*. 1998;59:41-45.
152. Meltzer H, Casey D, Garver D, Lasagna L, Marder S, Masand P, Miller D, Pickar D, Tandon R. Evaluating the effects of antipsychotics on cognition in schizophrenia. *J Clin Psychiatry*. 1998;59:35-40.
153. Meltzer H, Casey D, Garver D, Lasagna L, Marder S, Masand P, Miller D, Pickar D, Tandon R. Assessing the effects of atypical antipsychotics on negative symptoms. *J Clin Psychiatry*. 1998;59:28-34.
154. Meltzer H, Casey D, Garver D, Lasagna L, Marder S, Masand P, Miller D, Pickar D, Tandon R. Assessment of EPS and tardive dyskinesia in clinical trials. *J Clin Psychiatry*. 1998;59:23-27.
155. Meltzer H, Casey D, Garver D, Lasagna L, Marder S, Masand P, Miller D, Pickar D, Tandon R. Adverse effects of the atypical antipsychotics. *J Clin Psychiatry*. 1998;59:17-22.
156. Meltzer H, Casey D, Garver D, Lasagna L, Marder S, Masand P, Miller D, Pickar D, Tandon R. Clinical development of atypical antipsychotics: Research design and evaluation. *J Clin Psychiatry*. 1998;59:10-16.
157. Meltzer H, Casey D, Garver D, Lasagna L, Marder S, Masand P, Miller D, Pickar D, Tandon R. Measuring outcome in schizophrenia: Differences among the atypical antipsychotics. *J Clin Psychiatry*. 1998;59:3-9.
158. Masand PS, Sousou AJ, Gupta S, Kaplan DS. Irritable bowel syndrome and alcohol abuse or dependence. *Am J Drug Alcohol Abuse*. 1998;24(3):513-521.
159. Masand PS. Quetiapine. *J Clin Psychiatry*. 1998;59:687.
160. Gupta S, Masand PS, Rangwani S. Selective serotonin reuptake inhibitors in pregnancy and lactation. *Obstet Gyn Surv*. 1998;53(12):733-736.
161. Sipahimalani A, Masand PS. Olanzapine in the treatment of delirium. *Psychosomatics*. 1998;39(5):422-430.
162. Masand PS, Anand V, Tanquary J. Psychostimulant augmentation of second generation antidepressants: a case series. *Depress Anxiety*. 1998;7(2):89-91.

163. Masand PS. Atypical agents in the treatment of schizophrenia and other psychiatric disorders. *J Clin Psychiatry*. 1998;59:322-328.
164. Irwin M, Masand PS. Valproate and polycystic ovaries. *J Am Acad Child Adolesc Psychiatry*. 1998;37:1.
165. Masand PS, Bouckoms AJ, Fischel SV, Calabrese LV, Stern TA. A prospective multicenter study of competency evaluations by psychiatric consultation service. *Psychosomatics*. 1998;39(1):55-60.
166. Vasavada T, Masand PS, Nasra G. Evaluations of competency of patients with organic mental disorders. *Psychol Rep*. 1997; 80(1):107-113.
167. Masand PS. New antipsychotic agents should replace the neuroleptic agents for the first-line management of psychosis. *J Psychotic Dis*. 1997;1:16-17.
168. Sipahimalani A, Sime R, Masand PS. Treatment of delirium with risperidone. *Int J Geriatr Psychopharmacol*. 1997;1:24-26.
169. Masand PS, Gupta S. Dexfenfluramine for weight gain secondary to psychotropics. *Depress Anxiety*. 1997;6(3):119-123.
170. Bhandary AN, Fernandez F, Gregory RJ, Tucker P, Masand PS. Pharmacotherapy in adults with ADHD. *Psychiatr Ann*. 1997;27:545-555.
171. Sipahimalani A, Masand PS. Use of risperidone in delirium: case reports. *Ann Clin Psychiatry*. 1997;9(2):105-107.
172. Bhandary A, Masand PS. Buspirone in the management of disruptive behaviors due to Huntington's disease and other neurological disorders. *Psychosomatics*. 1997;38(4):389-391.
173. Gupta S, Masand PS, Kaplan D, Bhandary A. The relationship between schizophrenia and irritable bowel syndrome (IBS). *Schizophr Res*. 1997;23(3):265-268.
174. Masand PS, Vasavada T, Nasra G. Competency evaluations on the Psychiatric Consultation Service. *CNS Spectr*. 1997;2:50-53.
175. Gupta S, Masand PS. Olanzapine: Review of its pharmacology and indications in clinical practice. *Prim Psychiatry*. 1997;4:73-82.
176. Masand PS. Using newer antipsychotic agents in primary care. *Prim Psychiatry*. 1997;4:64-68.
177. Masand PS, Kaplan DS, Gupta S, Bhandary AN. Irritable bowel syndrome and dysthymia: is there a relationship? *Psychosomatics*. 1997;38(1):63-69.

178. Masand PS. Risperidone in the treatment of schizophrenia and other psychotic disorders. *Arch Indian Psychiatry*. 1996;3:72-89.
179. Masand PS, Kaplan D, Gupta S, Bhandary A. Relationship between irritable bowel syndrome (IBS) and double depression (dysthymia plus major depression). *Depression*. 1995/1996;3:303-306.
180. Masand PS, Tesar GE. Use of stimulants in the medically ill. *Psychiatr Clin North Am*. 1996;19(3):515-547.
181. Kaplan DS, Masand PS, Gupta S. The relationship of irritable bowel syndrome (IBS) and panic disorder. *Ann Clin Psychiatry*. 1996;8(2):81-88.
182. Bhandary A, Medicis J, Masand PS. Prescribing patterns of newer antidepressants in a resident managed adult psychiatry clinic. *Prim Psychiatry*. 1996;5:59-63.
183. Vasavada T, Masand PS, Chaudhary P. Psychiatric consultations in the very old. *Prim Psychiatry*. 1996;3:68-69.
184. Olin J, Masand PS. Psychostimulants for depression in hospitalized cancer patients. *Psychosomatics*. 1996;37:57-62.
185. Masand PS. Depression in long-term care facilities. *Geriatrics*. 1995;50(Suppl 1):S16-S24.
186. Masand PS, Reddy N, Gregory R. SSRI-induced sexual dysfunction successfully treated with amantadine. *Depression*. 1995;2:319-321.
187. Popli AP, Tanquary J, Lamparella V, Masand PS. Bupropion and anticonvulsant drug interactions. *Ann Clin Psychiatry*. 1995;7:99-101.
188. Handal N, Masand PS, Weilburg JB. Panic disorder and complex partial seizures: A truly complex relationship. *Psychosomatics*. 1995;36:498-502.
189. Masand PS, Kaplan D, Gupta S, Bhandary A, Nasra G, Kline M, Margo K. Major depression and irritable bowel syndrome (IBS): Is there a relationship? *J Clin Psychiatry*. 1995;56:363-367.
190. Masand PS, Pickett P, Murray GB. Hypomania precipitated by psychostimulant use in depressed medically ill patients. *Psychosomatics*. 1995;36:145-147.
191. Masand PS, Popli A, Weilburg JB. Sleepwalking (somnambulism): An overview. *Am Fam Physician*. 1995;51:649-654.
192. Masand PS, Chaudhary P. Methylphenidate treatment of post-stroke depression in a patient with global aphasia. *Ann Clin Psychiatry*. 1994;6:271-274.

193. Handal N, Masand PS, Weilburg J. Symptom overlap suggests complex link between panic disorder and seizures. *Neurol Rev.* 1994;2:10-11.
194. Masand PS, Stern A. Bupropion and secondary mania: is there a relationship? *Ann Clin Psychiatry.* 1993;5:271-274.
195. Masand PS. Successful treatment of sexual masochism and transvestic fetishism associated with depression with fluoxetine hydrochloride. *Depression.* 1993;1:50-52.
196. Masand PS. Psychostimulants, poststroke depression and side effects. *J Clin Psychiatry.* 1993;54:356.
197. Masand PS. Mania and hypothyroidism. *Psychosomatics.* 1993;34:374.
198. Vasavada T, Masand PS. An unusual variant of Capgras syndrome. *Perceptual and Motor Skills.* 1992;75:971-974.
199. Tanquary J, Lynch M, Masand PS. Obsessive compulsive disorder in relation to body dysmorphic disorder. *Am J Psychiatry.* 1992;149:1283-1284.
200. Popli A, Masand PS, Dewan M. Factitious disorder with psychological symptoms. *J Clin Psychiatry.* 1992;53:315-318.
201. Masand PS, Dewan M. Suicidality and fluoxetine revisited. *J Clin Psychiatry.* 1992;53:102-103.
202. Masand PS. Desipramine-induced oral pharyngeal disturbances: Stuttering and jaw myoclonus. *J Clin Psychopharmacol.* 1992;6:444-445.
203. Bouckoms AJ, Masand PS, Murray GB, Cassem EH, Tesar GE, Stern TA. Chronic non-malignant pain treated with long term oral narcotic analgesics. *Ann Clin Psychiatry.* 1992;4:185-192.
204. Masand PS, Pickett P, Murray GB. Psychostimulants for secondary depression in medical illness. *Psychosomatics.* 1991;32:203-208.
205. Masand PS, Murray GB, Pickett P. Psychostimulants in post-stroke depression. *J Neuropsychiatry Clin Neurosci.* 1991;3:23-27.
206. Dewan M, Masand PS. Prozac and suicide: The facts. *J Fam Practice.* 1991;33:312.
207. Masand PS, Dewan M. Association of fluoxetine with suicidal ideation. *Am J Psychiatry.* 1991;148:1603-1604.
208. Gupta S, Masand PS, Tanquary J. Thyroid hormone supplementation of fluoxetine in the treatment of major depression. *Br J Psychiatry.* 1991;159:866-867.

209. Masand PS, Gupta S, Dewan M. Suicidal ideation related to fluoxetine treatment. *N Engl J Med.* 1991;324:420.
210. Tanquary J, Masand PS. Paradoxical reaction to buspirone augmentation of fluoxetine. *J Clin Psychopharmacol.* 1990;10:377.
211. Pickett P, Masand PS, Murray GB. Psychostimulant treatment of geriatric depressive disorders secondary to medical illness. *J Geriatr Psychiatry Neurol.* 1990;3:146-151.
212. Masand PS, Murray GB, Stern TA, Bouckoms AJ. Sodium valproate for intractable hiccups. *Ann Clin Psychiatry.* 1990;2:135-137.

Submitted for Publication

1. Masand P, Gersing K, Burchett B, Pae C, Patkar A. Effectiveness of Escitalopram versus Venlafaxine XR in major depression in a real world clinical setting: A retrospective analysis.
2. Masand PS, Jefferson J, Kobak K, King M, Kaplan D, Gupta S. Assessing clinical trial outcomes with computer administered patient diaries.
3. Vidyaranya VM, Khanna S, Virk S, Virk JG, Kaplan D, Gupta S, Pinto C, Masand PS. Relationship of Irritable Bowel Syndrome (IBS) and Obsessive Compulsive Disorder in India.
4. Pinto C, Gupta S, Dhavale H, Kaplan D, Berry S, Masand PS. Schizophrenia and Irritable Bowel Syndrome: A cross cultural study.

Book Chapters

1. Masand PS, Christopher E, Clary G, Mago R, Patkar A. Mania, catatonia & psychosis in the medically ill. In: *Textbook of Psychosomatic Medicine*, 1st Ed. Levenson, J. L., ed. Washington, DC: American Psychiatric Publishing, Inc.; 2005.
2. Masand PS, Clary G, Chengappa R, Krishnan R. Somatic Therapies. In: Goldman LS, Wise TN, Brody DS, eds. *Psychiatry for Primary Care Physicians*, 2nd Ed. Illinois: AMA Press; 2004.
3. Masand PS, Weilburg J. Sleepwalking (somnambulism). In: Joseph AB, Young RR, eds. *Movement Disorders in Neuropsychiatry and Neurology*, 2nd Ed. Massachusetts: Blackwell Scientific Publication; 2003.
4. Masand PS. Common side effects of antipsychotics in the elderly. In: Vellas B, Fitten LJ, eds. *Research and Practice in Alzheimer's Disease and Other Dementias*, 1st Ed. Springer Publishing Company; 2001.
5. Dewan MJ, Masand PS. Pharmacological treatment of resistant depression. In: Ananth J, ed. *Textbook of Psychopharmacology*, 1st Ed. Mumbai, India: Jaypee Brothers; 1999.

6. Masand PS, Gupta S, Dewan MJ. Selective serotonin reuptake inhibitors (SSRIs). In: Ananth J, ed. *Psychopharmacology: Treatment of Psychiatric Disorders*, 1st Ed. Mumbai, India: Jaypee Brothers; 1999.
7. Masand PS, Chengappa R, Edwards W. Somatic treatments. In: Goldman L, Wise T, Brody DS., eds. *Handbook of Psychiatry in Primary Care*, 1st Ed. American Medical Association Press; 1998.
8. Masand PS, Weilburg J. Sleepwalking (Somnambulism). In: Joseph AB, Young RR, eds. *Movement Disorders in Neuropsychiatry and Neurology*, 1st Ed. Massachusetts: Blackwell Scientific Publication; 1992.
9. Masand PS. Current trends in psychosomatic research. In: Khanna S, Channabasavanna SM, Keshavan MS, eds. *Methods in Biological Psychiatry Research*, 1st Ed. McGraw-Hill Publishing Company; 1992.

Newsletters

1. Masand PS, Keck P. Jr., McIntyre R. Recovery vs. Recurrence: Optimizing Maintenance Therapy For Patients With Bipolar Disorder. *psychCME Reports*. September 2006.
2. Masand PS, Lieberman JA, Newcomer J. Dosing and Receptors: Lessons Learned from CATIE. *psychCME Reports*. September 2006.
3. Masand PS, Lieberman JA, McEvoy J. The CATIE Trial: Evidence to Guide Clinicians in the Management of Schizophrenia. *psychCME Reports*. June 2006.
4. Masand PS, Ghaemi SN, Stahl S. Fusing Evidence and Experience: Facing the Challenges of Mixed Episode Bipolar Disorder. *psychCME Reports*. March 2006.
5. Masand PS, Lieberman JA, Sharif Z. Making Real-Life Treatment Decisions About Schizophrenia: The CATIE Trial. *psychCME Reports*. March 2006.
6. Masand PS, Keck P. Jr., Rapaport MH. An Individualized Approach to the Psychological and Medical Challenges of Bipolar Disorder. *psychCME Reports*. February 2006.
7. Masand PS, Doghramji P, and Roth T. Wakefulness and Excessive Sleepiness: A Look at the Relationship and Its Impact on Our Patients. *psychCME Reports*. April 2005.
8. Masand PS, Beyer J, and Ghaemi SN. Raising the Bar for Patient Outcomes - Mixed Episodes in Bipolar Disorder: Trapped Between Two Worlds. *psychCME Reports*. April 2005.
9. Masand PS, Andreasen N, Conley R, and Jayaram G. Is Recovery an Achievable Goal in Schizophrenia? *psychCME Reports*. February 2005.

10. Masand PS, Bowden C, and Keck P. Jr., MD. Raising the Bar for Patient Outcomes: Expanding Choices in Bipolar Disorder. *psychCME Reports*. February 2005.
11. Masand PS, Meyer J, and Weiden P. Raising the Bar for Patient Outcomes—New Approaches to Understanding Metabolic Effects: Is It the Patient or the Medication? *psychCME Reports*. February 2005.
12. Masand PS, Keller M, and Lydiard RB. The Challenge of Managing the Complex Clinical Course of Generalized Anxiety Disorder. *psychCME Reports*. January 2005.
13. Masand PS, Lieberman J, and Perkins D. Raising the Bar for Patient Outcomes: When Switching Antipsychotics Makes Sense. *psychCME Reports*. November 2004.
14. Masand PS. Peter F. Buckley, MD and John Lauriello, MD. Aligning Patient and Clinician Goals in the Management of Schizophrenia. *psychCME Reports*. October 2004.
15. Masand PS, Weiden P, and Littrell K. Positioning the Treatment Team to Deliver Better Patient Outcomes: A Case-Based Approach. *psychCME Reports*. October 2004.
16. Masand PS. K. Ranga Krishnan, MD and Charles B. Nemeroff, MD, PhD. Raising the Bar for Patient Outcomes: The Evolving Role of Novel Antipsychotics in Treating Mood Symptoms. *psychCME Reports*. July 2004.
17. Masand PS, Keith S, and Potkin S. Oral or Long-Acting Injectable: Patient Selection for Long-Term Treatment Success. *psychCME Reports*. June 2004.
18. Masand PS, Weiden P, and Lieberman J. Switching for Success: An Evidence-Based Strategy. *psychCME Reports*. May 2004.
19. Masand PS, Green M, and Meltzer H. Breaking the Barriers to Optimal Patient Outcomes: Can Clinicians Impact Cognition? *psychCME Reports*. May 2004.
20. Masand PS, Ninan P, and O'Malley M. An Evidence-Based Strategy for Managing Residual Symptoms in Patients with Major Depression. *psychCME Reports*. April 2004.
21. Masand PS. Robert M. A. Hirschfeld, and Zimbroff D. Atypical Antipsychotics in Bipolar Disorder: Deciphering the Evidence. *psychCME Reports*. April 2004.
22. Masand PS, Kane J, and Turner M. Raising the Bar for Treatment Expectations in Schizophrenia. *psychCME Reports*. March 2004.

Selected Abstracts

1. “Does Shorter vs. Longer Stabilization in Patients with Bipolar I Disorder Predict Relapse?” Vieta E, Bowden CL, Masand PS, Everitt AL, Rahman Z, Eudicone JM, Baker RA, Forbes RA, Carlson BX. ECNP Annual Meeting, Paris, France, September 2011.
2. “Does Shorter vs. Longer Time to Stabilization in Patients with Bipolar I Disorder Predict Relapse Prevention? A Post-Hoc Analysis of an Adjunctive Aripiprazole Clinical Trial.” Masand PS, Tohen M, Everitt A, Baker R, Forbes R, Carlson B. NCDEU Annual Meeting, Boca Raton, FL, June 2011.
3. “Does Shorter vs. Longer Time to Stabilization in Patients with Bipolar I Disorder Predict Relapse Prevention?” Masand PS, Tohen M, Everitt A, Baker R, Forbes R, Carlson B. 9th International Conference on Bipolar Disorder, June 2011, Pittsburgh, PA.
4. “Achieving and Sustaining Remission in Bipolar I Disorder With Adjunctive Ziprasidone.” Masand P, O’Gorman C, Mandel F. American Psychiatric Association Annual Meeting, Honolulu, HI, May 2011.
5. “Achieving and Sustaining Remission in Bipolar I Disorder With Ziprasidone.” Masand PS, O’Gorman C, Mandel F. American College of Neuropsychopharmacology Annual Meeting, Hollywood, FL, December 2010.
6. “Ziprasidone for the Treatment of Acute Depressive Mixed State : A 6 Week Randomized Double-Blind Placebo-Controlled Trial.” Patkar AA, Gilmer W, Pae C, Ziffra M, Pirok E, Mulligan M, Peindl K, Filkowski M, Whitham E, Thommi S, Loebel A, Masand PS, Ghaemi SN. American College of Neuropsychopharmacology Annual Meeting, Hollywood, FL, December 2009.
7. “Predictors of remission in schizophrenia.” Masand P, O’Gorman C, Mandel F. American Psychiatry Association Annual Meeting, San Francisco, CA, May 2009.
8. “Predictors of remission in schizophrenia.” Masand P, O’Gorman C, Mandel F. International Congress on Schizophrenia Research (ICOSR) Meeting, San Diego CA, March 2009.
9. “Clinical trial reports in psychiatry before and after the CONSORT statement.” Han C, Pae CU, Bhatia K, Marks D, Oguejiofor C, Masand PS. American Psychiatry Association Annual Meeting, Washington DC, May 2008.
10. “Pregnancy and psychotropic medications.” Narasimhan M, Ballard F, Piendl K, Patkar A, Manelli P, Masand P. American Psychiatry Association Annual Meeting, Washington, DC, May, 2008.
11. “An open-label, rater-blinded, 6-week trial of escitalopram in major depression with atypical features.” Ajwani N, Pae CU, Masand PS, Peindl K, Mannelli P, Patkar AA. American Psychiatry Association Annual Meeting, San Diego, CA, May 2007.
12. “Sexual abuse, symptom severity and treatment response to paroxetine controlled release (CR) in irritable bowel syndrome (IBS).” Pae CU, Masand PS, Peindl K, Mannelli P, Patkar AA. American Psychiatry Association Annual Meeting, San Diego, CA, May 2007.

13. "Sexual abuse, health status and treatment response to paroxetine controlled release (CR) in fibromyalgia." Patkar AA, Pae CU, Krulewicz S, Peindl K, Mannelli P, Masand PS. American Psychiatry Association Annual Meeting, San Diego, CA, May 2007.
14. "Switching strategies to aripiprazole from other antipsychotics in stabilized schizophrenia: a randomized, 12 week, open label, parallel group study." Pae CU, Lim HK, Masand PS, Patkar AA, Lee C, Paik IH. American Psychiatry Association Annual Meeting, San Diego, CA, May 2007.
15. "Sexual abuse, health status and treatment response to paroxetine controlled release in fibromyalgia." Patkar AA, Peindl, K, Krulewicz S, Mannelli P, Pae CU, Masand PS. New Clinical Drug Evaluation Unit Annual Meeting, Boca Raton, FL, June 2007.
16. "Sexual abuse, symptom severity and treatment response to paroxetine controlled release in irritable bowel syndrome." Pae CU, Masand PS, Peindl K, Krulewicz S, Mannelli P, Patkar AA. New Clinical Drug Evaluation Unit Annual Meeting, Boca Raton, FL, June 2007.
17. "An open-label trial of aripiprazole in the treatment of autism and its correlation to whole blood serotonin levels and serotonin transporter (5HTTPLR) function." Narasimhan M, Bruce T, Ballard J, Patkar A, Masand P, Rech R. American College of Neuropsychopharmacology Annual Meeting, Hollywood, FL, December 2006.
18. "Sustained remission in bipolar I disorder: an post-hoc analysis of an aripiprazole bipolar study." Masand P, Eudicone J, Pikalov A, McQuade R, Vester-Blokland E, Carlson B. American College of Neuropsychopharmacology Annual Meeting, Hollywood, FL, December 2006.
19. "Effects of risperidone microspheres on polypharmacy and cognitive function." Wilson WH, McEvoy J, Keefe R, Byerly M, Masand P. American College of Neuropsychopharmacology Annual Meeting, Hollywood, FL, December 2006.
20. "Treatment compliance with atypical antipsychotics in patients with schizoaffective disorder." Masand PS, Peindl K, Narasimhan M, Patkar AA, Manelli P. Collegium Internationale Neuro-Psychopharmacologicum Annual Meeting, Chicago, IL, July 2006.
21. "Improving quality of life in individuals with bipolar disorder." Masand PS. Collegium Internationale Neuro-Psychopharmacologicum Annual Meeting, Chicago, IL, July 2006.
22. "Effectiveness of escitalopram versus venlafaxine XR in major depression in a real world clinical setting." Gersing K, Burchett B, Pae C, Patkar A. Collegium Internationale Neuro-Psychopharmacologicum Annual Meeting, Chicago, IL, July 2006.
23. "Issues related to treatment compliance in bipolar patients." Narasimhan M, Peindl K, Masand PS, Patkar A. Collegium Internationale Neuro-Psychopharmacologicum Annual Meeting, Chicago, IL, July 2006.

24. "A randomized double-blind, placebo-controlled trial of sodium oxybate in fibromyalgia syndrome (FMS)." Patkar AA, Bennett RM, Michalek JE, Cook H, Perera P, Masand P. Collegium Internationale Neuro-Psychopharmacologicum Annual Meeting, Chicago, IL. July 2006.
25. "Randomized, placebo-controlled, double-blind trial of paroxetine controlled release (CR) in irritable bowel syndrome." Peindl K, Krulewicz S, Varia I, Patkar A. Collegium Internationale Neuro-Psychopharmacologicum Annual Meeting, Chicago, IL, July 2006.
26. "A randomized, double-blind, placebo-controlled, flexible-dose, trial of augmentation with OROS methylphenidate in treatment resistant depression." Masand PS, Pae CU, Peindl K, Hooper-Wood C, Ciccone PE, Mannelli P, Patkar AA. Collegium Internationale Neuro-Psychopharmacologicum Annual Meeting, Chicago, IL, July 2006.
27. "Analysis of Remission in a 6-month double-blind continuation study of ziprasidone versus olanzapine." Masand PS, Loebel A. Collegium Internationale Neuro-Psychopharmacologicum Annual Meeting, Chicago, IL, July 2006.
28. "A comparison of tolerability profiles of patients with major depressive disorder receiving selective serotonin reuptake inhibitors (SSRIs) in a naturalistic clinical-care setting." Burchett B, Masand PS, Patkar AA, Pae CU, Gersing K. Collegium Internationale Neuro-Psychopharmacologicum Annual Meeting, Chicago, IL, July 2006.
29. "A comparison of tolerability profiles of patients with major depressive disorder receiving selective serotonin reuptake inhibitors (SSRIs) in a naturalistic clinical-care setting." Burchett B, Masand PS, Patkar AA, Pae CU, Gersing K. New Clinical Drug Evaluation Unit Annual Meeting, Boca Raton, FL, June 2006.
30. "A randomized, double-blind, placebo-controlled trial of sodium oxybate in fibromyalgia syndrome (FMS)." Patkar AA, Bennett RM, Michalek JE, Cook H, Perera P, Masand P. New Clinical Drug Evaluation Unit Annual Meeting, Boca Raton, FL, June 2006.
31. "A randomized, double-blind, placebo-controlled, flexible-dose trial of augmentation with OROS methylphenidate in treatment-resistant depression." Masand PS, Pae CU, Peindl K, Hooper-Wood C, Ciccone PE, Mannelli P, Patkar AA. New Clinical Drug Evaluation Unit Annual Meeting, Boca Raton, FL, June 2006.
32. "Randomized, double-blind, placebo-controlled trial of methylphenidate extended release (OROS MPH) in the treatment of antidepressant-related sexual dysfunction." Pae CU, Peindl K, Masand PS, Hooper-Wood C, Ciccone PE, Manelli P, Patkar AA. New Clinical Drug Evaluation Unit Annual Meeting, Boca Raton, FL, June 2006.
33. "A randomized, double-blind, placebo-controlled trial of sodium oxybate in fibromyalgia syndrome (FMS)." Patkar AA, Bennett RM, Michalek JE, Cook H, Parera P, Masand P. American Psychiatry Association Annual Meeting, Toronto, Canada, May 2006.

34. "A randomized, double-blind, placebo-controlled trial of methylphenidate extended release (OROS MPH) in treatment of antidepressant-related sexual dysfunction." Pae CU, Peindl K, Masand PS, Hooper-Wood C, Ciccone PE, Manelli P, Patkar AA. American Psychiatry Association Annual Meeting, Toronto, Canada, May 2006.
35. "Aripiprazole augmentation for patients with MDD who failed to respond to antidepressants therapy." Masand PS, Candace A, Lee C, Pae C, Paik I, Patkar A. American Psychiatry Association Annual Meeting, Toronto, Canada, May 2006.
36. "Issues related to treatment compliance in bipolar patients." Masand PS, Narasimhan M, Patkar A, Peindl K. American Psychiatry Association, Toronto, Canada, May 2006.
37. "A randomized, double-blind, placebo-controlled, flexible-dose, trial of augmentation with OROS methylphenidate in treatment resistant depression." Masand PS, Pae C, Peindl K, Hooper-Wood C, Ciccone P, Mannelli P, Patkar AA. American Psychiatry Association Annual Meeting, Toronto, Canada, May 2006.
38. "Analysis of remission in a six-month double-blind continuation study of ziprasidone versus olanzapine." Masand P, Loebel A. American Psychiatry Association Annual Meeting, Toronto, Canada, May 2006.
39. "Intramuscular pharmacotherapy of agitation in schizophrenia and bipolar disorders in psychiatric settings at Duke University Medical Center." Masand P, Burchett B, Gersing K, Tharwani H, Pae C, Patkar A. American Psychiatry Association Annual Meeting, Toronto, Canada, May 2006.
40. "Effectiveness of escitalopram versus venlafaxine XR in major depression in a real world clinical setting." Gersing K, Masand PS, Burchett B, Pae CU, Patkar AA. American Psychiatry Association Annual Meeting, Toronto, Canada, May 2006.
41. "A comparison of tolerability profiles of patients with major depressive disorder receiving selective serotonin reuptake inhibitors (SSRIs) in a naturalistic clinical care setting." Burchett B, Masand PS, Patkar AA, Pae CU, Gersing K. American Psychiatry Association Annual Meeting, Toronto, Canada, May 2006.
42. "History of depressive and anxiety disorders as predictors of response in fibromyalgia." Masand P, Ashwin A, Patkar, Kathleen Peindl, Stan Krulewicz, Paolo Mannelli, Amanda Lindsay. New Clinical Drug Evaluation Unit Annual Meeting, Boca Raton, FL, June 2005.
43. "Personality profiles as predictors of response for fibromyalgia." Masand P, Ruby Lekwauwa, Kathleen Peindl, Stan Krulewicz, Paolo Mannelli, Ashwin A, Patkar. New Clinical Drug Evaluation Unit Annual Meeting, Boca Raton, FL, June 2005.
44. "Pharmacotherapy of alzheimer's disease in 2004: What Clinicians Need to Know." Masand P, Tharwani H, Doraiswamy P, Patkar A, Mago R. American Psychiatry Association Annual Meeting, Atlanta, GA, May 2005.

45. "History of depressive and anxiety disorders as predictors of fibromyalgia." Masand P, Patkar A, Peindl K, Krulewicz S, Mannelli P, Lindsay A. American Psychiatry Association Annual Meeting, Atlanta, GA, May 2005.
46. "Psychiatric history as a predictor of drug response in irritable bowel syndrome." Masand P, Peindl K, Patkar A, Krulewicz S, Mannelli P, Varia I. American Psychiatry Association Annual Meeting, Atlanta, GA, May 2005.
47. "Personality profiles as predictors of response for fibromyalgia." Masand PS, Murray H, Patkar A, Peindl K, Krulewicz S, Dube E. American Psychiatry Association Annual Meeting, Atlanta, GA, May 2005.
48. "A survey of beliefs and practices regarding the use of second-generation antipsychotics." Masand P, Mago R, Patkar A, Fazal F, Mannelli P. American Psychiatry Association, Atlanta, GA, May 2005.
49. "A randomized, controlled trial of paroxetine CR in irritable bowel syndrome." Masand P, Peindl K, Krulewicz S, Mannelli P, Varia I, Patkar A. American Psychiatry Association Annual Meeting, Atlanta, GA, May 2005.
50. "Adverse drug effects." Masand PS, Chairman, American Psychiatry Association Annual Meeting, Atlanta, GA, May 2005.
51. "Treatment-refractory depression." Masand PS, Chairman, American Psychiatry Association Annual Meeting, Atlanta, GA, May 2005.
52. "Chronic pain syndromes: a psychiatric perspective." Masand PS, Chairman, American Psychiatry Association Annual Meeting, Atlanta, GA, May 2005.
53. "New outcomes in the treatment of schizophrenia: towards long-term re-integration of patients?" Masand PS, Chairman, 17th Congress of the European College of Neuropsychopharmacology, Stockholm, Sweden, October 2004.
54. "Ensuring adherence with long-acting formulation: a mandatory first step for long-term benefits?" Masand PS, Chairman, 17th Congress of the European College of Neuropsychopharmacology, Stockholm, Sweden, October 2004.
55. "The somatic face of anxiety." Masand PS. American Psychiatry Association Annual Meeting, New York, NY, May 2004.
56. "Safety considerations in treating the bipolar patient." Masand PS. American Psychiatry Association Annual Meeting, New York, NY, May 2004.
57. "Depression and anxiety in medical illness: the brain-body interface." Masand PS. American Psychiatry Association Annual Meeting, San Francisco, CA, May 2003.

58. "An evidence-based approach to Rational Polypharmacy in Schizophrenia." Masand PS. American Psychiatry Association Annual Meeting, San Francisco, CA, May 2003.
59. "Effects on weight change in patients switching from olanzapine to quetiapine." Masand PS. American Psychiatry Association Annual Meeting, San Francisco, CA, May 2003.
60. "Weight change in patients switching from olanzapine to quetiapine." Masand P, Gupta S, Virk S, Schwartz T, Hameed A, Frank BL, Lockwood K. New Clinical Drug Evaluation Unit Annual Meeting, Boca Raton, FL, June 2002.
61. "Paroxetine in patients with irritable bowel syndrome: a pilot study." Masand P, Virk S, Schwartz T, Gupta S, Lockwood K, Hameed A, King M, Kaplan DS, Beebe K. American Psychiatry Association Annual Meeting, Philadelphia, PA, May 2002.
62. "Newly admitted psychiatric patient prescriptions and pharmaceutical sales visits." Masand P, Schwartz T, Kuhles D, Wade M. American Psychiatry Association Annual Meeting, New Orleans, LA, May 2001.
63. "Relationship of irritable bowel syndrome (IBS) and major depression in Mumbai, India." Masand P, Sharma S, Pinto C, Virk S, Nihalani N, Gupta S, Kaplan D. American Psychiatry Association Annual Meeting, New Orleans, LA, May 2001.
64. "Does a pre-existing anxiety disorder predict response to paroxetine in IBS?" Masand P, Gupta S, Schwartz T, Kaplan D, Virk S, Hameed A, Lockwood K, Garakani A, Wade M. American Psychiatry Association Annual Meeting, New Orleans, LA, May 2001.
65. "Comparison of risperidone and olanzapine in bipolar and schizoaffective disorders." Masand P, Virk S, Wang X, Gupta S, Schwartz T, Hameed A, Wade M. American Psychiatry Association Annual Meeting, New Orleans, LA, May 2001.
66. "Assessing clinical trial outcomes with computer-assisted patient diaries." Masand P, Schwartz T, Gupta S, Kaplan D, Virk S, Kobak K, Jefferson J. American Psychiatry Association Annual Meeting, New Orleans, LA, May 2001.
67. "Prevalence of irritable bowel syndrome (IBS) in obsessive compulsive disorder." Masand P, Keuthen N, Gupta S, Virk S, Yu-Siao B, Bhatt N, Kaplan D. American Psychiatry Association Annual Meeting, New Orleans, LA, May 2001.
68. "Prescribing conventional antipsychotics at two veterans hospitals: are there geographical differences?" Schwartz TL, Arora M, Sharma A, Bhatia S, Hardoby W, Gupta S, Masand P. International Congress on Schizophrenia Research Annual Meeting, Whistler, British Columbia, April 2001.
69. "Prescribing conventional antipsychotics in the era of novel antipsychotics: informed consent issues." Masand P, Wang X, Schwartz TL, Virk S, Gupta S, Bradford F. International Congress on Schizophrenia Research Annual Meeting, Whistler, British Columbia, April 2001.

70. "Use of quetiapine in delirium." Masand PS. ECNP Annual Meeting, Munich, Germany, September 2000.
71. "Topiramate in bipolar disorder and schizoaffective disorder: mood stabilizing properties in treatment-refractory patients." Masand PS. Collegium Internationale Neuro-Psychopharmacologicum Annual Meeting, Brussels, Belgium, July 2000.
72. "Prescribing conventional antipsychotics at two veterans hospitals: are there geographic differences?" Masand P, Arora S, Wang X, Schwartz TL, Bhatia, Kuhles D, Agharkar B, Manjooran J, Hardoby W. Gupta S. Collegium Internationale Neuro-Psychopharmacologicum Annual Meeting, Brussels, Belgium, July 2000.
73. "Prescribing conventional antipsychotics in the era of novel antipsychotics: Informed consent issues." Masand P, Wang X, Kuhles D, Schwartz TL, Gupta S, Agharkar B. Collegium Internationale Neuro-Psychopharmacologicum Annual Meeting, Brussels, Belgium, July 2000.
74. "Treatment of delirium with quetiapine fumarate." Masand P, Schwartz TL. Collegium Internationale Neuro-Psychopharmacologicum Annual Meeting, Brussels, Belgium, July 2000.
75. "Comparison of risperidone and olanzapine in bipolar and schizoaffective disorders." Masand P, Wang X, Manjooran J, Schwartz T, Saba M, Hardoby W, Fredericks L, Ruetsch SE, Gupta S, Schults K, Devitt P, Berry S. Collegium Internationale Neuro-Psychopharmacologicum Annual Meeting, Brussels, Belgium, July 2000.
76. "Treatment of delirium with quetiapine fumarate." Masand P, Schwartz TL. New Clinical Drug Evaluation Unit Annual Meeting, Boca Raton, FL, May 2000.
77. "Comparison of risperidone and olanzapine in bipolar and schizoaffective disorders." Masand P, Wang X, Manjooran J, Schwartz T, Saba M, Hardoby W, Fredericks L, Ruetsch SE, Gupta S, Schults K, Devitt P, Berry S. New Clinical Drug Evaluation Unit Annual Meeting, Boca Raton, FL, May 2000.
78. "Comparison of risperidone and olanzapine in bipolar and schizoaffective disorders." Masand P, Wang X, Manjooran J, Schwartz T, Saba M, Hardoby W, Fredericks L, Ruetsch SE, Gupta S, Schults K, Devitt P, Berry S. Society of Biological Psychiatry Annual Meeting, Chicago, IL, May 2000.
79. "The relationship of irritable bowel syndrome (IBS) and obsessive compulsive disorder in India." Masand P, Vidyaranya A, Khanna, Virk J. American Psychiatric Association Annual Meeting, Chicago, IL, May 2000.
80. "The relationship of irritable bowel syndrome (IBS) and panic disorder in Mumbai, India." Masand P, Kubal, Virk S. American Psychiatric Association Annual Meeting, Chicago, IL, May 2000.

81. "Prescribing conventional antipsychotics at two veterans' hospitals: are there geographic differences?" Masand P, Arora S, Wang X, Schwartz TL, Bhatia, Kuhles D, Agharkar B, Manjooran J, Hardoby W, Gupta S. American Psychiatric Association Annual Meeting, Chicago, IL, May 2000.
82. "Prescribing conventional antipsychotics in the era of novel antipsychotics: informed consent issues." Masand P, Wang X, Kuhles D, Schwartz TL, Gupta S, Agharkar B. American Psychiatric Association Annual Meeting, Chicago, IL, May 2000.
83. "Bupropion SR for SSRI-induced sexual dysfunction: a randomized, double blind, placebo controlled, parallel group study." Masand P, Ashton A, Gupta S, Frank B. Annual Meeting of the American Psychiatric Association, Chicago, IL, May 2000.
84. "Treatment of delirium with quetiapine fumarate." Masand P, Schwartz TL. Annual Meeting of the American Psychiatric Association, Chicago, IL, May 2000.
85. "A comparison of risperidone and olanzapine in bipolar and schizoaffective disorders." Masand P, Wang X, Manjooran J, Schwartz T, Saba M, Hardoby W, Fredericks L, Ruetsch SE, Gupta S, Schults K, Devitt P, Berry S. Annual Meeting of the American College of Neuropsychopharmacology, Acapulco, Mexico, December 1999.
86. "A double-blind, placebo controlled trial of bupropion SR for SSRI-induced sexual dysfunction." Masand P, Ashton A, Gupta S, Frank D. Annual Meeting of the American College of Neuropsychopharmacology, Acapulco, Mexico, December 1999.
87. "Comparison of Risperidone and Olanzapine in bipolar and schizoaffective disorders." Masand P, Wang X, Manjooran J, Schwartz T, Saba M, Hardoby W, Fredericks L, Ruetsch SE, Gupta S, Schults K, Devitt P, Berry S. Annual Meeting of the World Psychiatric Association Meeting, Hamburg, Germany, August 1999.
88. "Use of atypical antipsychotics in a veterans affairs hospital." Masand P, Schwartz TL, Saba M, Hardoby W, Berry S. Annual Meeting of the American Psychiatric Association, Washington, DC, May 1999.
89. "Clinical effectiveness of divalproex sodium versus lithium carbonate in bipolar spectrum disorders." Masand P, Schwartz TL, Boylan D, Kuhles DJ, Gupta S, Chenappa KNR, Ahmed S, Parepally H. Annual Meeting of the American Psychiatric Association, Washington, DC, May 1999.
90. "Typical patients - atypical care: An interactive case study." Masand P, Chair of Symposium. Annual Meeting of the American Psychiatric Association, Washington, DC, May 1999.
91. "Schizophrenia and irritable bowel syndrome: A cross-cultural study." Masand PS, Pinto S, Gupta S, Dhavale H, Kaplan D, Berry SL. Biennial Meeting of the International Congress on Schizophrenia Research, Sante Fe, NM, April 1999.

92. "Olanzapine in the treatment of delirium." Masand P, Sipahimalani A. Annual Meeting of the Academy of Psychosomatic Medicine, Buena Vista, FL, November 1998.
93. "Cross-cultural comparison of irritable bowel syndrome in India." Masand P. Annual Meeting of the Academy of Psychosomatic Medicine, Orlando, FL, November 1998.
94. "New research findings in schizophrenia." Masand P. Annual Meeting of the American Psychiatric Nurses Association, Orlando, FL, October 1998.
95. "Use of atypical antipsychotics in dementia." Masand P. Annual Meeting of the American Geriatric Society, Seattle, Washington, May 1998.
96. "Use of novel antipsychotic in dementia and delirium." Masand P. Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 1998.
97. "Divalproex sodium versus valproic acid: Is there a difference for mood stabilization?" Masand P, Schwartz T, Massa J, Gupta S, Al-Samarrai S. Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 1998.
98. "Relationship of schizophrenia and irritable bowel syndrome: A cross-cultural comparison." Masand P, Pinto C, Dhavale H, Gupta S, Kaplan D. Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 1998.
99. "Olanzapine and delirium." Masand P, Sipahimalani A. Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 1998.
100. "Update on antidepressants." Masand P. Annual Meeting of the Symposia of the Annual Meeting on Physicians Health Care, American Medical Association, Victoria, British Columbia, April 1998.
101. "Update on the SSRIs." Masand P. Annual Meeting of the Regional Meeting of the World Psychiatric Association, Jaipur, India, January 1998.
102. "Prolactin and schizophrenia." Masand P. Annual Meeting of the Regional Meeting of the World Psychiatric Association, Jaipur, India, January 1998.
103. "Recent advances in the endocrinology of schizophrenia." Masand P. Annual Meeting of the Regional Meeting of the World Psychiatric Association, Jaipur, India, January 1998.
104. "Psychosis and agitation in the elderly." Masand P. Annual Meeting of the American Society of Hospital Pharmacists, Philadelphia, November 1997.
105. "Use of atypical antipsychotics in conditions other than schizophrenia." Masand P. Annual Meeting of the American Psychiatric Association, San Diego, CA, May 1997.

106. "Clinical and neuropsychological improvement unrelated to SPECT in OCD." Masand P, Dewan M, Tanquary JF, Sprafkin R, Thomas D, Szeverenyi M, Major L. Annual Meeting of the American Psychiatric Association, San Diego, CA, May 1997.
107. "Use of risperidone in forensic patients." Masand P, Devitt P. Annual Meeting of the American Psychiatric Association, San Diego, CA, May 1997.
108. "Treatment of delirium with risperidone." Masand P, Sipahimalani A, Sime R. Annual Meeting of the American Psychiatric Association, San Diego, CA, May 1997.
109. "Depression across the reproductive life cycle: correlations between events." Gregory RJ, Yohai N, Masand P. Annual Meeting of the Academy of Psychosomatic Medicine, San Antonio, TX, November 1996.
110. "Prospective multicenter study of competency evaluations by the Psychiatric Consultation Service." Masand PS, Bouckoms A, Fischel SV, Calabrese L, Stern TA. Annual Meeting of the Academy of Psychosomatic Medicine Annual Meeting, San Antonio, TX, November 1996.
111. "Update on risperidone." Masand P. Annual Meeting of the Indian Psychiatric Society, Bangalore, India, January 1996.
112. "IBS and panic disorder: is there a relationship?" Masand P. Annual Meeting of the Biological Psychiatry Section Meeting of the World Psychiatric Association, Bombay, India, January 1996.
113. "Update on risperidone." Masand P. Annual Meeting of the Biological Psychiatry Section Meeting of the World Psychiatric Association, Bombay, India, January 1996.
114. "The relationship between IBS and dysthymia." Masand P. Annual Meeting of the Biological Psychiatry Section Meeting of the World Psychiatric Association, Bombay, India, January 1996.
115. "Depression in the medically ill." Masand P. Annual Meeting of the Biological Psychiatry Section Meeting of the World Psychiatric Association, Bombay, India, January 1996.
116. "Treatment resistant depression." Masand P. Annual Meeting of the Biological Psychiatry Section Meeting of the World Psychiatric Association, Bombay, India, January 1996.
117. "Relationship between dysthymia and irritable bowel syndrome (IBS)." Masand P, Gupta S, Kaplan D, Bhandary A. Annual Meeting of the Academy of Psychosomatic Medicine, Palm Springs, CA, November 1995.
118. "Treatment strategies in the pharmacological management of brain trauma." Masand P, Bhandary AN, Fernandez F, Gregory RJ. Annual Meeting of the American Academy of Clinical Psychiatry, San Diego, CA, October 1995.

119. "Current perspectives in the pharmacological treatment of adults with attention deficit hyperactivity disorder." Masand P, Bhandary AN, Fernandez F, Gregory RJ. Annual Meeting of the American Academy of Clinical Psychiatry, San Diego, CA, October 1995.
120. "Obsessive compulsive disorder: Combination pharmacotherapy with SSRI and psychostimulant." Masand P, Bhandary AN, Gregory RJ. Annual Meeting of the American Academy of Clinical Psychiatry, San Diego, CA, October 1995.
121. "Buspirone in the management of disruptive behaviors." Masand P, Bhandary AN. Annual Meeting of the American Academy of Clinical Psychiatry, San Diego, CA, October 1995.
122. "Treatment strategies in the pharmacological management of adults with attention deficit hyperactivity disorder." Masand P, Bhandary AN, Fernandez F, Gregory RJ. Annual Meeting of the Institute of Psychiatric Services, Boston, MA, October 1995.
123. "Panic disorder and IBS: Is there a relationship?" Masand P, Gupta S, Kaplan D, Bhandary A. Annual Meeting of the American Academy of Gastroenterology, New York City, October 1995.
124. "The relationship between schizophrenia and irritable bowel syndrome (I.B.S.)." Gupta S, Masand P, Kaplan D, Bhandary A. Annual Meeting of the International Congress on Schizophrenia Research, Warm Springs, VA, April 1995.
125. "Do neurological impaired schizophrenics have abnormal SPECT scans?" Masand P, Dewan M, Thomas FD, Szeverenyi N, Bhandary A, Major LF. Annual Meeting of the International Congress on Schizophrenia Research, Warm Springs, VA, April 1995.
126. "The relationship between double depression (dysthymia plus major depression) and irritable bowel syndrome (I.B.S.)." Masand P, Kaplan D, Gupta S, Bhandary A. Annual Meeting of the American Psychosomatic Society, New Orleans, LA, March 1995.
127. "A comparison study of constant observation in three urban centers." Lamdan RM, Ramchandani D, O'Dowd MA, McKegney FP, Masand P. Annual Meeting of the Academy of Psychosomatic Medicine, Phoenix, AZ, November 1994.
128. "Psychiatric consultations in the very old." Masand P, Vasavada T, Chaudhary P. Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 1994.
129. "Neuropsychological correlates of abnormal SPECT findings in schizophrenia." Masand P, Dewan M, Thomas D, Tanquary J, Szeverenyi N, Lynch M, Bhandary A, Major LF. Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 1994.
130. "Do neurologically impaired schizophrenics have abnormal SPECT scans?" Masand P, Dewan M, Thomas FD, Tanquary J, Szeverenyi N, Lynch M, Bhandary A, Major LF. Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 1994.

131. "Prescribing patterns of newer antidepressants in a resident outpatient psychiatry clinic." Masand P, Bhandary A, Medicis J. Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 1994.
132. "Complex partial seizures and panic disorder: a truly complex relationship." Masand P, Handal N, Weilburg J. Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 1994.
133. "Major depression and irritable bowel syndrome: is there a relationship?" Masand P, Kaplan D, Gupta S, Bhandary A, Nasra G, Kline M, Margo K. Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 1994.
134. "SPECT and neuropsychological changes after behavior therapy or clomipramine treatment in OCD patients." Masand P, Dewan M, Thomas D, Tanquary J, Szeverenyi N, Lynch M, Bhandary A, Major LF. Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 1994.
135. "Neuropsychological correlates of abnormal SPECT findings in schizophrenia." Dewan M, Masand P, Thomas FD, Tanquary J, Szeverenyi N, Lynch M, Bhandary A, Major LF. Annual Meeting of the Society of Biological Psychiatry, Philadelphia, PA, May 1994.
136. "Do neurologically impaired schizophrenics have abnormal SPECT scans?" Masand P, Dewan M, , Thomas FD, Tanquary J, Szeverenyi N, Lynch M, Bhandary A, Major LF. Annual Meeting of the Society of Biological Psychiatry, Philadelphia, PA, May 1994.
137. "Psychostimulants for secondary depression in cancer patients." Olin J, Masand P. Annual Meeting of the Academy of Psychosomatic Medicine, New Orleans, November 1993.
138. "Competency evaluations in patients on the psychiatric consultation service." Masand P, Vasavada T, Nasra G. Annual Meeting of the Institute of Hospital and Community Psychiatry, Baltimore, Maryland, October 1993.
139. "Competency evaluations in patients with organic mental syndromes." Masand P, Vasavada T, Nasra G. Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 1993.
140. "Bupropion revisited - How much is too much?" Masand P, Popli A, Lamparella V, Tanquary J. Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 1993.
141. "Do SPECT findings in schizophrenia have clinical relevance?" Masand P, Thomas FD, Tanquary JF, Wasenko J, Lynch MR, Dewan M, Major LF. Annual Meeting of the Society of Biological Psychiatry, San Francisco, CA, May 1993.
142. "Competency evaluations in geriatric patients," Masand P, Nasra G, Vasavada T. Annual Meeting of the American Association of Geriatric Psychiatry, New Orleans, LA, February 1993.
143. "Competency evaluations in geriatric patients seen by the psychiatric consultation service," Masand P, Nasra G, Vasavada T. Annual Meeting of the State University of New York (S.U.N.Y.), Upstate Medical University, Syracuse, NY, December 1992.

144. "Competency evaluations in patients with organic mental disorder seen by the psychiatric consultation service," Masand P, Vasavada T, Nasra G. Annual Meeting of the State University of New York (S.U.N.Y.), Upstate Medical University, Syracuse, NY, December 1992.
145. "Simple surface markers for aligning MRI and SPECT," Masand P, Falon S, Szeverenyi N, Lynch M, Thomas D, Tanquary J, and Dewan M. Annual Meeting of the Society of Biological Psychiatry, Annual Meeting, Washington, DC, April 1992.
146. "Long-term narcotics for non-malignant pain," Masand P, Bouckoms A, Murray GB, and Stern T. Annual Meeting of the International Conference on Psychosomatic Medicine, 50th Annual Meeting of American Psychosomatic Society, New York, April 1992.
147. "Clomipramine-induced normalization of asymmetry on SPECT in OCD," Masand PS. State University of New York (SUNY) Annual Meeting, Upstate Medical University, Syracuse, NY, December 1991.
148. "Clomipramine-induced normalization of asymmetry on SPECT in OCD," Masand P, Lynch M, Tanquary J, Thomas D, and Dewan M. Third World Congress International Brain Research Organization Annual Meeting, Montreal, Canada, August 1991.
149. "Use of psychostimulants in depressed medically ill patients," Masand P, Pickett P, Murray GB. State University of New York (SUNY) Annual Meeting, Upstate Medical University, Syracuse, NY, November 1989.

TELEVISION APPEARANCES

1. "Far Have We Come? Issues in Adherence to Antidepressant Treatment: Focus on Tolerability and Quality of Life." Prakash S. Masand, MD, Moderator. Faculty participants: Alan Schatzberg, MD and Alexander Bodkin, MD. December 18, 2007.
2. "Advances in the Identification and Management of Pediatric Psychotic and Mood Disorders: Childhood-Onset Schizophrenia, Childhood-Onset Bipolar Disorder, and the Schizophrenia Prodrome." Prakash S. Masand, MD, Moderator. Faculty participants: Christoph Correll, MD and Kiki Chang, MD. November 27, 2007.
3. "Novel Approaches to the Treatment of Major Depressive Disorder: Beyond SSRIs and SNRIs." Prakash S. Masand, MD, Moderator. Faculty participants: Madhukar Trivedi, MD and Craig Nelson, MD. November 13, 2007.
4. "Remission and Recovery in Bipolar Disorder: Current Clinical Evidence for Optimizing Treatment." Prakash S. Masand, MD, Moderator. Faculty participants: Roger McIntyre, MD and Richard Shelton, MD. September 13, 2007.

5. "Diagnostic and Management Challenges in Major Depression: New Treatment Strategies." Prakash S. Masand, MD, Moderator. Faculty participants: Michael Thase, MD and John Beyer, MD. July 17, 2007.
6. "Endocrine Adverse Effects of Atypical Antipsychotic Agents." Prakash S. Masand, MD, Moderator. Faculty participants: P. Murali Doraiswamy, MD and David Henderson, MD. June 5, 2007.
7. "Pharmacodynamics of Atypical Antipsychotics: Sedation versus Efficacy." Prakash S. Masand, MD, Moderator. Faculty participants: John Kane, MD and Zafar Sharif, MD. May 15, 2007.
8. "Strategies for Dosing and Switching Antipsychotics for Optimal Clinical Management." Prakash S. Masand, MD, Moderator. Faculty participants: Peter Buckley, MD and Christoph Correll, MD. April 24 2007.
9. "Akathisia: Problem of History or Concern of Today." Prakash S. Masand, MD, Moderator. Faculty participants: Tim Lambert, MD and Naveed Iqbal, MD. February 6, 2007.
10. "Pharmacotherapy: Roadmap to Individualized Treatment with Antipsychotics," (Part 2). Prakash S. Masand, MD, Moderator. Faculty participants: Sheldon H. Preskorn, MD and John P. Docherty, MD. October 11, 2006.
11. "Pharmacotherapy: Roadmap to Recovery from Schizophrenia," (Part 1). Prakash S. Masand, MD, Moderator. Faculty participants: Stephen R. Marder, MD and Peter J. Weiden, MD. July 19, 2006.
12. "Recovery vs. Recurrence: Optimizing Maintenance Therapy for Patients with Bipolar Disorder." Prakash S. Masand, MD, Moderator. Faculty participants: Paul E. Keck, Jr., MD and Roger McIntyre, MD, FRCPC. May 3, 2006.
13. "Exploring the Neurocircuitry of the Brain and Its Impact on Treatment Selections in ADHD." Prakash S. Masand, MD, Moderator. Faculty participants: Peter S. Jensen, MD and Stephen M. Stahl, MD, PhD. March 1, 2006.
14. "Dosing and Receptors: Lessons Learned from CATIE." Prakash S. Masand, MD, Moderator. Faculty participants: Jeffrey Lieberman, MD and John Newcomer, MD. January 25, 2006.
15. "A Surgeon General's Perspective: Achieving Remission in Depression." Prakash S. Masand, MD, Moderator. Faculty participants: David Satcher, MD, PhD and Jeffrey Kelsey, MD, PhD. December 15, 2005.
16. "Raising the Bar for Patient Outcomes- Mixed Episodes in Bipolar Disorder: Trapped Between Two Worlds." Prakash S. Masand, MD, Moderator. Faculty participants: John Beyer, MD and S. Nassir Ghaemi, MD, MPH. December 8, 2005.
17. "The Pathophysiology of Sleep Disturbances: A Focus on Insomnias." Prakash S. Masand, MD, Moderator. Faculty participants: S. Nassir Ghaemi, MD, MPH and Stephen M. Stahl, MD, PhD.

December 7, 2005.

18. "The Pathophysiology of Sleep Disturbances: A Focus on Insomnias." Prakash S. Masand, MD, Moderator. Faculty participants: Andrew Krystal, MD and Thomas Roth, PhD. December 1, 2005.
19. "Making Real-World Treatment Decisions About Schizophrenia: The CATIE Trial." Prakash S. Masand, MD, Moderator. Faculty participants: Jeffrey A. Lieberman, MD and Zafar Sharif, MD-Faculty. November 9, 2005
20. "Linking Genes, Receptors, and Treatments in the Management of ADHD." Prakash S. Masand, MD, Moderator. Faculty participants: Joseph Biederman, MD and Jeffrey Newcorn, MD-Faculty. October 11, 2005.
21. "An Individualized Approach to the Psychological and Medical Challenges of Bipolar Disorder." Prakash S. Masand, MD, Moderator. Faculty participants: Paul E. Keck, Jr., MD and Mark Hyman Rapaport, MD. October 5, 2005.
22. "A Surgeon General's Perspective on the Unmet Needs of Patients with Anxiety Disorders." Prakash S. Masand, MD, Moderator. Faculty participants: David Satcher, MD, PhD and Pedro L. Delgado, MD. September 7, 2005.
23. "Making Real-World Treatment Decisions About Schizophrenia: The CATIE Trial." Prakash S. Masand, MD, Moderator. Faculty participants: Jeffrey A. Lieberman, MD and Diana O. Perkins, MD, MPH. August 24, 2005.
24. "Reducing Relapse: Case-Based Strategies for Achieving Successful Long-Term Outcomes in Patients with Schizophrenia." Prakash S. Masand, MD, Moderator. Faculty participants: John M. Kane, MD. August 10, 2005.
25. "Schizophrenia and Bipolar Disorder: The Convergence of Medication Strategies." Prakash S. Masand, MD, Moderator. Faculty participants: Peter F. Buckley, MD and Roger S. McIntyre, MD, FRCPC. July 6, 2005.
26. "A Surgeon General's Perspective on Cultural Competency: What Is It and How Does It Affect Diagnosis and Treatment of Major Depressive Disorder?" Prakash S. Masand, MD, Moderator. Faculty participants: David Satcher, MD, PhD and Philip T. Ninan, MD. June 1, 2005.
27. "Excessive Sleepiness: Assessing Its Impact on Patient Wellness." Prakash S. Masand, MD, Moderator. Faculty participants: Mary B. O'Malley, MD, PhD and Daniel J. Buysse, MD. May 18, 2005.
28. "The Impact of the Treatment Team in Redefining Remission and Recovery in Schizophrenia." Prakash S. Masand, MD, Moderator. Faculty participants: Peter F. Buckley, MD and Kathleen S. Jarboe, APRN, BC. April 20, 2005.

29. "Medical Ethics in Mental Health Practice." Prakash S. Masand, MD, Moderator. Faculty participants: Mark S. Komrad, MD. April 6, 2005.
30. "Raising the Bar for Patient Outcomes: When Switching Antipsychotics Makes Sense." Prakash S. Masand, MD, Moderator. Faculty participants: Jeffrey Lieberman, MD and Diana O. Perkins, MD, MPH. March 23, 2005.
31. "A Surgeon General's Perspective on the Impact of Race, Ethnicity, and Culture on Mental Illness." Prakash S. Masand, MD, Moderator. Faculty participants: David Satcher, MD, PhD and Geetha Jayaram, MD. February 16, 2005.
32. "Wakefulness and Excessive Sleepiness: A Look at the Relationship and Its Impact on Our Patients." Prakash S. Masand, MD, Moderator. Faculty participants: Paul P. Doghramji, MD, FAAFP and Thomas Roth, PhD. January 26, 2005.
33. "A Surgeon General's Perspective: Achieving Remission in Depression." Prakash S. Masand, MD, Moderator. Faculty participants: David Satcher, MD, PhD and Jeffrey Kelsey, MD, PhD. December 15, 2004.
34. "Raising the Bar for Patient Outcomes—Mixed Episodes in Bipolar Disorder: Trapped Between Two Worlds." Prakash S. Masand, MD, Moderator. Faculty participants: John Beyer, MD and S. Nassir Ghaemi, MD, MPH. December 8, 2004.
35. "The Pathophysiology of Sleep Disturbances: A Focus on Insomnias." Prakash S. Masand, MD, Moderator. Faculty participants: Andrew Krystal, MD and Thomas Roth, PhD. December 1, 2004.
36. "Raising the Bar for Patient Outcomes: Expanding Choices in Bipolar Disorder." Prakash S. Masand, MD, Moderator. Faculty participants: Charles Bowden, MD and Paul E. Keck, Jr., MD. November 10, 2004.
37. "Understanding the Challenges of Bipolar Disorder throughout the Female Life Cycle." Prakash S. Masand, MD, Moderator. Faculty participants: Deborah T. Combs Cantrell, MD, PA and Zachary Stowe, MD. October 27, 2004.
38. "Is Recovery and Achievable Goal in Schizophrenia? Prakash S. Masand, MD – Moderator. Faculty participants: Nancy C. Andreasen, MD, PhD, Robert R. Conley, MD and Geetha Jayaram, MD. September 29, 2004.
39. "Treatment Resistant Depression: Can Adjunctive Therapies Help Achieve Remission?" Prakash S. Masand, MD, Moderator. Faculty participants: Roger McIntyre, MD, FRCPC and Mark Hyman Rapaport, MD. September 22, 2004.
40. "Raising the Bar for Patient Outcomes—New Approaches to Understanding Metabolic Effects: Is it the Patient or the Medication?" Prakash S. Masand, MD, Moderator. Faculty participants: Peter Weiden, MD and Jonathan Meyer, MD. September 1, 2004.

41. "A Surgeon General's Perspective on the Impact of Race, Ethnicity, and Culture on Mental Illness." Prakash S. Masand, MD, Moderator. Faculty participants: David Satcher, MD, PhD and Geetha Jayaram, MD. August 18, 2004.
42. "An Appraisal of the Impact of Comorbid Sleep Disturbances and Anxiety Disorders." Prakash S. Masand, MD, Moderator. Faculty participants: Daniel J. Buysse, MD and Jonathan Davidson, MD. August 4, 2004.
43. "Aligning Patient and Clinician Goals in the Management of Schizophrenia." Prakash S. Masand, MD, Moderator. Faculty participants: Peter F. Buckley, MD and John Lauriello, MD. July 21, 2004.
44. "Raising the Bar for Patient Outcomes: When Switching Antipsychotics Makes Sense." Prakash S. Masand, MD, Moderator. Faculty participants: Jeffrey Lieberman, MD and Diana O. Perkins, MD, MPH. June 16, 2004.
45. "Unmasking Bipolar Depression." Prakash S. Masand, MD, Moderator. Faculty participants: Mark A. Frye, MD and Terence A. Ketter, MD. June 9, 2004.
46. "Positioning the Treatment Team to Deliver Better Patient Outcomes: A Case-Based Approach." Prakash S. Masand, MD, Moderator. Faculty participants: Peter J. Weiden, MD and Kimberly Littrell, MS, ARNP, CS. May 26, 2004.
47. "A Surgeon General's Report on the Stigma of Mental Illness: Have We Made Progress?" Prakash S. Masand, MD, Moderator. Faculty participants: David Satcher, MD, PhD and Larry Culpepper MD, MPH. May 12, 2004.
48. "Raising the Bar for Patient Outcomes: The Evolving Role of Novel Antipsychotics in Treating Mood Symptoms." Prakash S. Masand, MD, Moderator. Faculty participants: K. Ranga Krishnan, MD and Charles B. Nemeroff, MD, PhD. April 14, 2004.
49. "Achieving Lasting Stability in the Bipolar Patient: Long-Term Issues and Expectations." Prakash S. Masand, MD, Moderator. Faculty participants: Charles Bowden, MD and Roger S. McIntyre, MD, FRCPC. March 24, 2004.
50. "Battling Bipolar Disorder: Evidence for New Treatments and Tactics." Prakash S. Masand, MD, Moderator. Faculty participants: Pierre Chue, MD, MRCPsych, FRCPC, DABPN and Trisha Suppes, MD, PhD. March 10, 2004.
51. "Oral or Long-Acting Injectable: Patient Selection for Long-Term Treatment Success." Prakash S. Masand, MD, Moderator. Faculty participants: Samuel J. Keith, MD and Steven G. Potkin, MD. February 25, 2004.
52. "Breaking the Barriers to Optimal Patient Outcomes: Can Clinicians Impact Cognition?" Prakash S. Masand, MD, Moderator. Faculty participants: Michael F. Green, PhD and Herbert Y. Meltzer, MD.

February 18, 2004.

53. "An Evidence-Based Strategy for Managing Residual Symptoms in Patients with Major Depression." Prakash S. Masand, MD, Moderator. Faculty participants: Mary B. O'Malley, MD, and Philip Ninan, MD. January 28, 2004.

PROFESSIONAL AWARDS AND SPECIAL RECOGNITION

- Outstanding Academician of the Year Award, Indo American Psychiatric Association, 2008
- Best Doctors in America, 2005-2006 database, Best Doctors, Inc., USA
- *Best Doctors in North Carolina*, 2004-2005 Edition, Best Doctors, Inc., Boston, MA
- *America's Top Psychiatrists*, 2004-2005 Edition, Consumer's Research Council of America, Washington, D.C.
- Continuing Faculty Development Award, NYS/UUP Professional Development and Quality of Working Life Committee, 2000
- Continuing Faculty Development Award, NYS/UUP Professional Development and Quality of Working Life Committee, 1998
- Psyche Award: Excellence in the Contribution to the Residents Study of Psychiatry, 1997 - 1998
- Continuing Faculty Development Award, NYS/UUP Professional Development and Quality of Life Committee, 1995
- Elected as Fellow of the Academy of Psychosomatic Medicine, 1994
- Term Faculty Development Award, NYS/UUP Professional Development and Quality of Working Life Committee, 1993
- Psyche Award: Excellence in the Contribution to the Residents Study of Psychiatry, 1990 - 1991
- Best Debater at All-India Intercollegiate Literary Festival held in New Delhi, December, 1981
- President of Literary and Debating Society, Topiwala National Medical College, July, 1980 - June 1981
- Best Debater (M.S. Kekre trophy) at T.N. Medical College, 1980
- Class President at Topiwala National Medical College, July 1979-1980

ELECTED POSITIONS AND COMMITTEE INVOLVEMENT

- President, Central New York District Branch, American Psychiatric Association, 1995-1996
- Elected as Fellow of the Academy of Psychosomatic Medicine, 1994
- President Elect, Central New York District Branch, American Psychiatric Association, 1994-1995
- American Psychiatric Association Subcommittee for Joint Sponsorship of Continuing Medical Education, 1994 - 1996
- Psycho-Oncology Core Committee, Cancer and Leukemia Group (CALGB), 1993 - 1995
- Awards Committee, Annual Clinical Research Award, American Academy of Clinical Psychiatrists, 1993 - 1995
- Research Committee, Academy of Psychosomatic Medicine, 1992 - 1995

COURSES TAUGHT

1. Psychobiology and Neuroscience course. PGY III, Department of Psychiatry, Long Island Jewish-Hillside Hospital 2010-present

2. Case Conference. PGY IV, Department of Psychiatry, Long Island Jewish-Hillside Hospital 2010-present
3. Psychopharm II course. PGY II, Department of Psychiatry, Saint Vincent's Hospital 2009-2010
4. Chairman's Rounds PGY II-IV, Department of Psychiatry, Duke University Medical Center 2002-present
5. Psychopharmacology Didactics PGY II-III, Department of Psychiatry, Duke University Medical Center 2001- present
6. Advanced Psychopharmacology weekly rounds, PGY III-IV, State University of New York (S.U.N.Y.), Upstate Medical University, Department of Psychiatry, 1995-1999
7. Psychopharmacology Case Conference, Outpatient Clinic, University Hospital, 1991-1999
8. Lecturer, State University of New York (S.U.N.Y.), Upstate Medical University, Introduction to Clinical Psychiatry course, 1991 - 1999
9. Lecturer, State University of New York (S.U.N.Y.), Upstate Medical University, MS II, Behavioral Foundations of Medicine course, 1991 - 2001
10. Tutor, State University of New York (S.U.N.Y.), Upstate Medical University, MS II, Medical Humanities Course, Introduction to Clinical Medicine, 1990-1991
11. Resident supervision and case conferences, Syracuse V.A. Psychopharmacology Clinic, 1989-1991
12. Lecturer, State University of New York (S.U.N.Y.), Upstate Medical University, Advanced Clinical Psychiatry course, 1989-1999
13. Lecturer, State University of New York (S.U.N.Y.), Upstate Medical University, Introduction to Clinical Psychopharmacology course, 1989-1999
14. Supervisor, State University of New York (S.U.N.Y.), Upstate Medical University, Psychiatric Residents, PGY 1-PGY IV, 1989 - Present
15. Supervisor, State University of New York (S.U.N.Y.), Upstate Medical University, MS IV Elective in Consultation Psychiatry, 1989-1999
16. Supervisor, State University of New York (S.U.N.Y.), Upstate Medical University, MS III Consultation Psychiatry Clerkship, 1989-1999
17. Lecturer, State University of New York (S.U.N.Y.), Upstate Medical University, MS III Psychiatric Clerkship Lecture Series, 1989-1999

18. Supervisor, Harvard Medical School Student Consultation Psychiatry rotation, Massachusetts General Hospital, 1988-1989

SPEAKING ENGAGEMENTS

Invited to present at more than 2,000 meetings, conferences, symposia, and events in the United States and abroad. Selected presentations listed below.

1. WFSBP 2011, Prague, Czech Republic, June 2011.
 - Debate: Antidepressants are not associated with suicide risk.
2. American Psychiatric Association Annual Meeting, New Orleans, LA, May 2010
 - “New Developments in Schizophrenia Research and Practice: From the Pipeline to the Clinic,” Symposium Chairman
 - Switching Antipsychotic Therapy: Lessons for the Clinician
3. CINP Meeting, Hong Kong, June 2010
 - “Advances in the Treatment of Bipolar Disorder,” Symposium Chairman
 - “Mixed States Within Bipolar Disorder: The Role of Atypical Antipsychotics”
4. American Psychiatric Association Annual Meeting, San Diego, CA, May 2007
 - “Psychosis in the Medically Ill”
 - “How do Atypical Antipsychotics Work: From Receptors to Reality”
 - “Diagnostic Pitfalls in Bipolar Disorder”
 - “Pharmacologic Predictability of Antipsychotic-Related Adverse Effects: An Opportunity for Improving Outcomes”
5. ECNP Meeting, Paris, France, September 2006
 - “Are All Atypical Antipsychotics Created Equal?”
6. American Psychiatric Association Annual Meeting, Toronto, Canada, May 2006
 - “Atypical Antipsychotics: 2006 and Beyond”
 - “Health, Nutrition, and Weight in Schizophrenia”
 - “The Maze of Mood and Anxiety in the Elderly Patient: A Case Series”
7. University Malaya Medical Center, Kuala Lumpur, Malaysia, July 2005
 - “Shifting Paradigms in the Treatment of Schizophrenia: From Relapse Prevention to Long-term Functional Recovery”
8. Meeting of the Royal College of Thai Psychiatrists, Bangkok, Thailand, July 2005
 - “Improving Adherence and Long-term Outcome of Schizophrenia”
9. Annual Meeting of the American Psychiatric Association, Atlanta, GA May 2005
 - “Chronic Pain Syndromes: A Psychiatric Perspective”

10. Annual Meeting of the Korean College of Neuro-psychopharmacology, Ulsan, South Korea, March 2005
 - “Update on Paxil-CR in Mood and Anxiety Disorders”
11. Tomorrow’s World Today, London, England, March 2005
 - “Improving Compliance in Patients with Schizophrenia”
12. Grand Rounds, Department of Medicine, Duke University Medical Center, Durham, NC, March 2005
 - “Current Controversies in Treating Depression”
13. Nordic Psychiatry Academy 2005, Copenhagen, Denmark, January 2005
 - “Improving Non-compliance: The Major Barrier to Long-term Outcome in Bipolar Disorder”
14. Taipei Psychiatric Association Meeting, Taipei, Taiwan, January 2005
 - “Treating Behavioral and Psychological Symptoms of Dementia”
15. Hong Kong Psychiatric Society, Hong Kong, January 2005
 - “Improving Long-term Outcome in Patients with Schizophrenia”
16. Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2003
 - “Neuropsychiatry in the Age of Poly-Pharmacy,” Symposium Chairman
 - “Depression and Anxiety in Medical Illness: The Brain-Body Interface”
 - “An Evidence-Based Approach to Rational Poly-Pharmacy in Schizophrenia”
17. Grand Rounds, St. Elizabeth’s Hospital, Washington DC, April 2003
 - “Should Side Effects Be the Key Determining Factor in Choosing the Ideal Antipsychotic?”
18. Grand Rounds, Department of Psychiatry, University of Hawaii, Honolulu, Hawaii, April 2003
 - “Treating Schizophrenia in the New Millennium”
19. Department of Psychiatry, University of Hawaii, April 2003
 - “The Role of Atypical Antipsychotics in Treating Bipolar Disorder”
 - “The Relationship of Irritable Bowel Syndrome in Psychiatric Illness
 - “The Role of Stimulants in the Medically Ill”
20. Northern California Psychiatric Association Meeting, San Francisco, CA, March 2003
 - “Current Controversies in Treating Depression”
21. Annual Meeting of the Malaysia Psychiatric Society, Kuala Lumpur, Malaysia, January 2003
 - “Recent Advances in the Treatment of Schizophrenia”
22. Annual Meeting Indian Psychiatric Society, Hyderabad, India, January 2002
 - “Role of Novel Antipsychotics in Treating Bipolar Disorder”

23. U.S. Psychiatric Congress, Las Vegas, NV, October 2002
 - “Should Side Effects be the Key Determining Factor in Choosing the Ideal Antipsychotic?”
 - “Managing Compliance to Achieve Success: The Role of Side Effects”
24. XII World Congress of Psychiatry, Yokohama, Japan, August 2002
 - “Challenging symptoms in juvenile and elderly patients: a patient-centered approach for improved outcomes,” Symposium Chair
 - “Treating schizophrenia in the new millennium”
 - “EPS and first episode schizophrenia”
 - “Pharmacotherapy of BPSD: moving beyond antipsychotics”
25. American Psychiatric Association Annual Meeting, Philadelphia, PA, May 2002
 - “Side Effects of Novel Antipsychotics: Movement Disorders and Metabolic Concerns”
 - “Management of Depression in the Medically Ill: Practical Approaches to Treatment”
 - “Can Long-term Outcome be Improved in Depression? The Role of Side Effects and Compliance”
 - “Clinical Challenges in Depression”
26. AAGP Annual Meeting, Orlando, FL, February 2002
 - “Use of Antipsychotics in the Elderly”
27. Meeting of the Austrian Society of Neuropharmacology, Vienna, Austria, November 2001
 - “Atypical Antipsychotics: How do They Work and for What?”
28. Duke University Medical Center Symposium, Syracuse, NY, November 2001
 - “The Long-term Adverse Affects of Novel Antipsychotics”
29. Grand Rounds, University of North Carolina Chapel Hill, Chapel Hill, NC, October 2001
 - “Treating Depression in the Medically Ill”
30. Distance Learning Network, Nationwide Teleconference, October 2001
 - “Novel Antipsychotics: Long-term Adverse Effects and Metabolic Concerns”
31. APA-IPS, Orlando, FL, October 2001
 - “Novel Antipsychotics: Acute to Long-term Management,” Symposium Chair
 - “Long-term Management of Depression”
32. Japanese American Medical Association, Hiroshima, Japan, October 2001
 - “Comparison of Healthcare in the United States and Japan,” Round-table Discussion
33. Meet the Expert Session, International Psychogeriatric Association Meeting, Nice, France, September 2001
 - “Treating Agitation in Dementia”
34. Biological Psychiatry Meeting, Berlin, Germany, July 2001

- “Use of Novel Antipsychotics in Manic Psychosis”
35. American Psychiatric Association Annual Meeting, New Orleans, LA, May 2001
 - “Depression in the Medically Ill”
 36. American Geriatric Society Annual Meeting, Chicago, IL, May 2001
 - “Treating Behavioral Disturbances in Dementia”
 37. University of British Columbia, Vancouver, British Columbia, April 2001
 - “Role of Cholinesterase Inhibitors in Treating Dementia”
 38. Grand Rounds, Thomas Jefferson University, Philadelphia, PA, January 2001
 - “Current Controversies in Treating Depression”
 39. Global Psychopharmacology Conference, Barcelona, Spain, November 2000
 - “Use of Novel Antipsychotics in Delirium”
 40. Grand Rounds, Strong Memorial Hospital, Rochester, NY, November 2000
 - “Current Controversies with SSRI’s”
 41. Symposia at the APA-IPS Meeting, Philadelphia, PA, October 2000.
 - “Long-term Treatment of Depression”
 42. Canadian Psychiatric Association Annual Meeting, Victoria, British Columbia, October 2000
 - “Comparison of Novel Antipsychotics”
 43. Association of Irish Psychiatrists, Killarney, Ireland, September 2000
 - “Treating Schizophrenia in the New Millennium”
 44. Third World Congress on Stress, Dublin, Ireland, September 2000
 - “Schizophrenia: A Biopsychosocial Illness”
 45. European College of Neuropsychopharmacology Annual Meeting, Munich, Germany, September 2000
 - “The Side Effect Burden of Novel Antipsychotics”
 46. CINP, Brussels, Belgium, July 2000
 - “Are All Atypical Antipsychotics Created Equal?”
 47. World Alzheimer’s Congress, Washington, D.C., July 2000
 - “Treating Agitation and Dementia”
 48. Annual Meeting of the American Association of Physicians of India Origin, New York, NY, July 2000.
 - “Pharmacotherapy of Aggression”

49. American Psychiatric Association Annual Meeting, Chicago, IL, May 2000
 - “Psychosis Associated with Schizophrenia”
 - “Pharmacotherapy of Agitation in Dementia”
50. Annual Meeting of the Australian Psychiatric Society, March 2000
 - “Use of Novel Antipsychotics in Bipolar Disorders”
51. Quebec Psychiatric Society Annual Meeting, Quebec City, Canada, May 2000
 - “Are All Atypical Antipsychotics Created Equal?”
52. Psychiatric Society of Virginia Annual Meeting, Richmond, VA, April 2000
 - “Long-term Management of Schizophrenia”
53. American Association of Geriatric Society Annual Meeting, Miami, FL, March 2000
 - “Dementia: Expanding the Boundaries,” Chair
 - “Pharmacotherapy of Agitation in Dementia”
54. Psychiatric Society of Guangzhou, February 2000
 - “Use of Novel Antipsychotics in Bipolar Disorders”
55. Hong Kong Psychiatric Society, Hong Kong, February 2000
 - “Use of Novel Antipsychotics in Bipolar Disorders”
56. Asia Pacific Psychopharmacology Conference, Kuala Lumpur, Malaysia, February 2000
 - “Novel Antipsychotics: Exceeding Expectations”
57. Annual CME Symposium of the American Association of Physicians from India, Las Vegas, NV, January 1999
 - “Update on Irritable Bowel Syndrome”
58. Indiana Psychiatric Society Annual Meeting, Indianapolis, IN, September 1999
 - “Common Errors in Treating Psychosis”
59. Grand Rounds, Duke University School of Medicine, Durham, NC, March 1999
 - “Use of Atypical Antipsychotics in Non-Schizophrenic Conditions”
60. U.S. Psychiatric Congress, Orlando, FL, November 1997
 - “Use of Atypical Antipsychotics in the Elderly”
61. Grand Rounds, Hospitals at the University of Pennsylvania, Philadelphia, July 1997
 - “Update on Newer Antipsychotics”
62. Western New York Psychological Association Annual Meeting, April 1997
 - “Recent Advances in Neuropharmacology”

63. Psychopharmacology Grand Rounds, McLean Hospital, Belmont, MA, February 1996
 - “Sleep Disorders in Psychiatric Patients”
64. Grand Rounds, University of Virginia, Charlottesville, VA, October 1995
 - “Advances in the Treatment of Schizophrenia”
65. Psychiatric Association of Puerto Rico, San Juan, September 1995
 - “Pharmacotherapy of Depression in the 21st Century”
66. Joint Grand Rounds of Departments of Neurosurgery, Medicine, Cardiology and Psychiatry, T.N. Medical College, Bombay, India, January 1995
 - “The Brain-Heart Connection”
67. Delhi Psychiatric Society, New Delhi, India, December 1994
 - “Long-term Treatment of Depression”
68. G.S. Medical College, University of Bombay, India, April 1992
 - “Obsessive Compulsive Disorder - Current Trends in Diagnosis and Treatment”
69. Department of Neurology, State University of New York (S.U.N.Y.), Upstate Medical University, Syracuse, NY, May 1991
 - “Mood Disorders”
70. Department of Psychiatry, State University of New York (S.U.N.Y.), Upstate Medical University, Syracuse, NY, August 1989
 - “Use of Psychostimulants in Depressed Medically Ill Patients”
71. Department of Psychiatry, State University of New York, Upstate Medical University, Syracuse, NY, April 1986
 - “Treatment Resistant Depression”

RESEARCH GRANTS AND CONTRACTS

<u>Title</u>	<u>Sponsor</u>	<u>Role</u>	<u>Duration</u>
Escitalopram for Irritable Bowel Syndrome	Forest Pharmaceuticals	Co-Investigator	09/01/04-
Escitalopram for Crohn’s Disease	Forest Pharmaceuticals	Co-Investigator	01/01/04-
Methylphenidate for SSRI Resistant Depression	Ortho McNeil	Sub-Principal Investigator	05/01/03
Paroxetine-CR in the Treatment of Irritable	Glaxo SmithKline	Co-Investigator	05/01/02-

Bowel Syndrome Paroxetine-CR in the Treatment of Fibromyalgia	Glaxo SmithKline	Co-Investigator	04/01/02-
Citalopram in Patients with Irritable Bowel Syndrome (IBS): A Pilot, Open-Label Study	Forest Pharmaceuticals	Principal Investigator	01/01/01- 12/31/02
Chart Reviews of the Risperidone versus Olanzapine in 3 Settings	Janssen Pharmaceutica	Principal Investigator	02/28/01- 06/30/01
Paroxetine for Depression in Schizophrenia: an Open- Label Study	Glaxo SmithKline	Principal Investigator	02/08/00 - 02/28/01
A Double-Blind Placebo Control Study of a Flexible Dose of Venlafaxine ER in Adult Outpatient with Generalized Social Anxiety Disorder	Wyeth-Ayerst	Principal Investigator	02/14/00- 02/15/01
Switch Study: Olanzapine to Quetiapine	Astra Zeneca	Principal Investigator	01/03/00 - 01/02/01
RIS-USA-T191 Conventional Anti- psychotics Study	Janssen Pharmaceutica	Principal Investigator	10/01/99- 09/30/00
Paroxetine for Irritable Bowel Syndrome: A Pilot, Open-Label Study	Glaxo SmithKline	Principal Investigator	08/01/99 - 07/31/00
Bupropion SR Versus Placebo for SSRI Induced Sexual Dysfunction	Glaxo SmithKline	Principal Investigator:	01/01/98 - 06/30/99

PROFESSIONAL MEMBERSHIPS

- Academy of Psychosomatic Medicine
- American Academy of Clinical Psychiatrists
- American Association of Physicians from India
- American Psychiatric Association
- American Psychosomatic Society

- American Society of Clinical Psychopharmacology

ACADEMIC/ADMINISTRATIVE ACTIVITIES AT THE UNIVERSITY LEVEL

1. Director, psychCME, the leading program on continuing medical education, 2001 – 2004
2. Organized CME Conferences on Anxiety Disorders, 2001
3. Organized CME Conference on Psychopharmacology, 2000
4. Organized CME Conferences on Social Anxiety Disorder, Atypical Antipsychotics, Mood Disorders, Psychopharmacology, 1999
5. Organized CME conferences on Psychopharmacology, 1996
6. Organized CME conferences on Depression, Schizophrenia, Bipolar Disorders, 1995
7. Organized CME conferences on OCD, Depression, Anxiety Disorders, Women's Issues in Mental Health, 1994
8. CME Committee, Hutchings Psychiatric Center, 1994 - 1999
9. Managed Care Committee, 1994-1997
10. Secretary/Treasurer District Branch American Psychiatric Association, 1993-1994
11. Chairman, Membership Committee, District Branch, American Psychiatric Association, 1992-1993
12. Clinical Trials Advisory Committee, 2001
13. Executive Committee, 1992-1999
14. Appointments and Promotions Committee, 1997-2001
15. Pharmacy and Therapeutics Committee, State University of New York (S.U.N.Y.), Upstate Medical University, Syracuse, 1998-1999
16. Quality Review Council, State University of New York (S.U.N.Y.), Upstate Medical University, Syracuse, 1995 -1996
17. Graduate Education Committee, 1992-1999
18. Research Committee, 1992 - 2001
19. Continuing Education and Program Committee, 1989-1992

20. Undergraduate Education Committee, 1989 - 1999